KLC4-Related Early-Childhood-Onset Neurodegeneration

Mendelian MONDO:0700288 Pathograph 12 Show in embeddings browser

A childhood-onset multisystem neurodegenerative disorder caused by biallelic truncating KLC4 variants, known from a single consanguineous family. KLC4 encodes kinesin light chain 4, one of the four cargo-binding light-chain subunits of the kinesin-1 motor, and the reported allele - a 19-base-pair deletion in exon 6 - introduces a stop codon that removes the tetratricopeptide repeats through which the light chain binds cargo adaptors. Two things about this entry's scope need stating before anything else, because both are unusual. First, the disease's own name is more specific than its published clinical description. MONDO and OMIM call it "early-childhood-onset neurodegeneration with retinitis pigmentosa, sensorineural hearing loss, and demyelinating peripheral neuropathy", and MedGen attributes that description to the single 2015 report. That report's abstract describes the three affected siblings only as having "progressive complicated spastic paraplegia"; its full text is behind a paywall and cannot be quoted. The nearest independently published statement of the phenotype is a later paper's summary - patients show defects in vision, hearing, movement and cognition - and that is the level at which the phenotype records below are curated. Retinitis pigmentosa, the sensorineural character of the hearing loss, and the demyelinating character of the neuropathy are all in the disease's name and none is supported by a source this entry can quote. Second, OMIM itself treats the gene-phenotype relationship as unconfirmed. NCBI's `mim2gene_medgen` maps MIM 621129 to KLC4 with the comment `question`, which the file's own documentation defines as "A question mark, '?', before the disease name indicates an unconfirmed or possibly spurious mapping". One family, one allele, and no replication in the eleven years since. ClinVar does hold a second KLC4 allele classified against this disease concept - `NM_201521.3:c.1164T>A` (p.Cys388Ter), likely pathogenic - but a PubMed search for KLC4 turned up no publication describing that patient, so it does not enter this entry as evidence. What is well supported is the cell biology. KLC4 is expressed broadly in developing central and peripheral neurons, and a zebrafish klc4 mutant shows that it is required for stabilising nascent axon branches, for normal microtubule dynamics and endosomal transport, and for the contact repulsion that lets peripheral sensory arbors tile. The fish's authors read the human disease as a disorder of developmental patterning rather than of bulk cargo transport - which fits a multisystem sensory and motor phenotype, and sits awkwardly with the word "neurodegeneration" in the disease name, since the fish mutant is adult viable with no early degeneration at all. A separate KLC4 story should not be merged into this one. A man reported in 2023 through the Undiagnosed Diseases Network had slowly progressive myelopathy and neuropathy from around age fifty, carrying a *heterozygous* frameshift at residue 369 - a different allele, a different inheritance mode, and a different age of onset by half a century. Both truncations are predicted to remove the same cargo-binding domain, which is why the two are discussed together in the literature, but they are not the same disease and this entry does not curate the late-onset case as one.

Ask OpenScientist

Ask a research question about KLC4-Related Early-Childhood-Onset Neurodegeneration. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Mappings
1
Inheritance
5
Pathophys.
4
Phenotypes
3
Gaps
12
Pathograph
1
Genes
1
Medical Actions
2
Models
3
References
1
Deep Research
🔗

Mappings

MONDO
MONDO:0700288 early-childhood-onset neurodegeneration with retinitis pigmentosa, sensorineural hearing loss, and demyelinating peripheral neuropathy
skos:exactMatch MONDO
👪

Inheritance

1
Autosomal recessive HP:0000007
A homozygous KLC4 deletion in three affected siblings of one consanguineous family, with both unaffected parents and two unaffected siblings heterozygous and a third unaffected sibling homozygous wild type. That is complete segregation within the family, and the unaffected heterozygotes are what makes the mode recessive rather than dominant with reduced penetrance. Only one family has been reported, so nothing can be said about penetrance, expressivity or de novo rate.
Autosomal recessive inheritance
Show evidence (2 references)
PMID:26423925 SUPPORT Human Clinical
"Meanwhile, the unaffected parents and two siblings were heterozygous and one sibling was homozygous wild type."
The segregation result. Carrier parents and an unaffected homozygous-wild-type sibling together establish recessive inheritance in this pedigree.
PMID:37565267 SUPPORT Other
"An additional family was previously reported where a premature stop codon after residue 277 of KLC4 caused HSP in an autosomal-recessive manner; heterozygous family members did not have any symptoms (Bayrakli et al., 2015)."
An independent group's reading of the same pedigree, which matters here because it is the sentence that separates this recessive entity from the heterozygous late-onset case the same paper reports. Graded OTHER because it summarises prior work rather than reporting a new observation.
?

Discussions and Knowledge Gaps

3
MONDO and OMIM name this disease after retinitis pigmentosa, sensorineural hearing loss and demyelinating peripheral neuropathy. The abstract of its only clinical publication names none of the three. Where did they come from, and what should a curator do about it?
KNOWLEDGE GAP klc4_disease_name_outruns_its_published_phenotype
Attached to
disease#KLC4-Related Early-Childhood-Onset Neurodegeneration phenotypes#Visual Impairment phenotypes#Hearing Impairment
MedGen's definition of this concept attributes the full description - progressive walking difficulty, retinitis pigmentosa with blindness, sensorineural hearing loss, demyelinating peripheral neuropathy, severely impaired intellectual development - to Bayrakli et al. 2015. That is the same publication this entry cites. So the features are almost certainly in the paper's full text, in a clinical table or case descriptions that its abstract compresses into the four words "progressive complicated spastic paraplegia". The paper is behind a paywall and its full text cannot be retrieved into the reference cache, and a dismech evidence snippet must be an exact substring of a cached source. So the entry cannot curate retinitis pigmentosa, sensorineural hearing loss or demyelinating neuropathy, even though the disease is named after them and they are very likely true. What it can do is curate one level up. A later zebrafish paper summarises the human phenotype as defects in vision, hearing, movement and cognition, and that sentence is quotable. The three phenotype records here are bound accordingly - HP:0000505 rather than a retinal dystrophy term, HP:0000365 rather than a sensorineural one - and each says in its description why. This is a resolvable gap, not a permanent one, and the resolution is mechanical: obtain the 2015 full text, cache it, and split the visual, auditory and peripheral nerve records to the specificity it supports. Until then, a reader should treat the disease's own name as the best available hypothesis about its phenotype rather than as something this entry has verified. One lead for whoever does that work. The falcon deep-research report committed alongside this entry had retrieval access to the 2015 paper's full text and reports retinitis pigmentosa progressing to blindness in the oldest patient, described in 3 of 3 affected siblings, alongside sensorineural hearing loss and demyelinating polyneuropathy. That is a provider report, not a source this entry can quote, and it is recorded here as a lead rather than as evidence - but it is consistent with MedGen's attribution and says the full text is worth obtaining.
Show evidence (2 references)
PMID:26423925 SUPPORT Human Clinical
"Three patients from the same family shared common features of progressive complicated spastic paraplegia."
The whole of the abstract's clinical description. The gap is the distance between this sentence and the disease's four-feature name.
PMID:36222498 SUPPORT Other
"Multiple neural systems are affected in the human disease caused by KLC4 mutation; patients show defects in vision, hearing, movement and cognition (Bayrakli et al., 2015)."
The intermediate level of description that is quotable, and the reason this entry curates four organ systems rather than either one phenotype or four named diagnoses.
KLC4 has two published patients: three siblings homozygous for a residue-277 truncation with early-childhood multisystem disease, and one man heterozygous for a residue-369 truncation with myelopathy and neuropathy from age fifty. One gene, two truncations predicted to do the same thing, two inheritance modes, and fifty years between the onsets. Are these one disease or two?
KNOWLEDGE GAP klc4_two_alleles_two_inheritance_modes
Attached to
pathophysiology#Loss of the KLC4 Cargo-Binding TPR Domain genetic#KLC4 animal_models#Humanized hKLC4 Caenorhabditis elegans
This entry curates them as two, and the reason is dosage. The recessive family's unaffected heterozygous parents and siblings are the control the dominant case lacks: if one truncated KLC4 allele were sufficient to cause disease, four heterozygous relatives should not have been well. So either the residue-369 allele does something the residue-277 allele does not - a dominant-negative effect on the kinesin complex rather than simple loss - or something else contributes in that proband. Both possibilities are live in the literature and neither is settled. The 2023 paper raises the dominant-negative reading itself and says it could not be tested in the worm, because the truncated transcript is likely destroyed by nonsense-mediated decay. It also reports that other variants were found by genome sequencing in the same individual and that their contribution is under investigation - and notes his celiac disease and occupational herbicide and pesticide exposure, both of which can produce myelopathy and neuropathy. The practical consequence for this entry is a boundary rather than a mystery: the late-onset case is not curated as a phenotype, prevalence entry or subtype of this disease, and the C. elegans model is linked only to the molecular domain-loss node with fidelity LOW, because the allele it tests is that patient's rather than this family's. What would resolve it is a second recessive family, or a functional comparison of the two truncated proteins in the same system with wild-type protein co-expressed - the experiment that separates loss of function from dominant negative, and the one the worm model explicitly could not perform.
Show evidence (4 references)
PMID:37565267 SUPPORT Human Clinical
"We identified an individual with late-onset HSP with a heterozygous variant in KLC4 predicted to cause a frame shift at residue 369, closely followed by a premature stop codon."
The second patient, whose allele and inheritance mode differ from this disease's.
PMID:37565267 SUPPORT Human Clinical
"A male individual with the clinical KLC4 variant presented to the Undiagnosed Diseases Network (UDN) with slowly progressive myelopathy and neuropathy"
His presentation, which is separated from this disease's by roughly fifty years of onset and by the absence of visual, auditory and cognitive involvement.
PMID:37565267 SUPPORT Other
"The truncated KLC4 protein variant could conceivably be acting in a dominant-negative manner in the proband, which would not be recapitulated in C. elegans owing to likely nonsense-mediated decay of the transcript."
The mechanism that would reconcile the two inheritance modes, together with the reason it remains untested. Graded OTHER because the sentence is the authors' interpretive discussion rather than a result from either their human or their worm arm.
+ 1 more reference
The klc4 mutant zebrafish is adult viable with no early neurodegeneration, and its defect is one of axon patterning rather than axon survival. The human disease is called a neurodegeneration. Which is right about KLC4?
HUMAN MODEL MISMATCH klc4_zebrafish_patterning_versus_human_neurodegeneration
Attached to
animal_models#klc4 mutant zebrafish pathophysiology#Disordered Patterning Across Multiple Neural Systems phenotypes#Progressive Complicated Spastic Paraplegia
The fish authors are explicit that their mutant's neurons look healthy, that axons grow faster rather than slower, and that there is no sign of early degeneration - and they read the human disease accordingly, as possibly caused by defects in developmental patterning rather than by degeneration. The human report describes a progressive disorder, and the disease's name in MONDO and OMIM begins with the word neurodegeneration. These need not be contradictory. A developmental patterning defect can present as progressive loss of function if a mispatterned circuit decompensates with age or fails to keep pace with growth, and "progressive" in the clinical report is a description of course, not of pathology. No neuropathology from an affected person has been published, so no one has looked at whether neurons are actually dying. But they are different mechanistic claims with different consequences, and the entry does not choose between them. The pathograph is built on the patterning account, because that is where the measurements are, and the fish's viability is curated as a FAILS_TO_RECAPITULATE link against the spastic paraplegia phenotype rather than omitted. Two caveats belong with the mismatch. Fish have no corticospinal tract, so the absence of spastic paraplegia in the model is partly a fact about its anatomy. And vertebrates carry four kinesin light chains with overlapping neuronal expression, so paralogue redundancy may differ between species - the fish may simply be better compensated than a child.
Show evidence (3 references)
PMID:36222498 SUPPORT Model Organism
"Klc4 mutant neurons do not have a general growth defect, in that their axons grow faster than wild type axons. In addition, klc4 mutants are adult viable and show no signs of early neurodegeneration."
The negative result at the centre of the mismatch.
PMID:36222498 SUPPORT Model Organism
"Our results also give insight into mechanisms of the human disease caused by KLC4 mutation, which may be caused by defects in developmental patterning."
The alternative reading of the human disease that the model supports, hedged by its own authors.
PMID:26423925 SUPPORT Human Clinical
"Three patients from the same family shared common features of progressive complicated spastic paraplegia."
The word "progressive" is the whole of the published evidence that this disease is degenerative, and it describes a clinical course rather than a pathology.
⚙

Pathophysiology

5
KLC4 Homozygous Truncating Deletion
A homozygous 19-base-pair deletion in exon 6 of KLC4, c.853_871del19, found by homozygosity mapping followed by whole-exome sequencing in a consanguineous family. The deletion generates a stop codon, so both the transcript and the protein are truncated. It is the only allele reported in a published patient with this disease.
KLC4 hgnc:21624 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves KLC4 (hgnc:21624). hgnc:21624 is a gene from the HUGO Gene Nomenclature Committee.
Downstream
Loss of the KLC4 Cargo-Binding TPR Domain
Show evidence (2 references)
PMID:26423925 SUPPORT Human Clinical
"Whole-exome sequencing revealed a homozygous mutation (c.853_871del19) in the gene coding the kinesin light chain 4 protein (KLC4)."
The allele, and the gene it identifies.
PMID:26423925 SUPPORT Human Clinical
"The 19 bp deletion in exon 6 generates a stop codon and thus a truncated messenger RNA and protein."
The molecular consequence, stated at both the transcript and the protein level. The truncated transcript matters because nonsense-mediated decay may remove it altogether, which is the difference between a null and a dominant-negative allele.
Loss of the KLC4 Cargo-Binding TPR Domain
The kinesin light chains carry six tetratricopeptide repeats that bind cargo adaptor proteins, and they also activate the motor by relieving autoinhibition of the kinesin heavy chain. A stop codon after residue 277 removes those repeats. This is a prediction from the position of the truncation rather than a measurement: no patient material has been assayed for KLC4 protein, cargo binding or motor activity.
kinesin I complex GO:0016938 Gene Ontology (GO) Relation: this pathophysiological event involves this cellular component This pathophysiological event involves kinesin I complex (GO:0016938). GO:0016938 is a cellular component from the Gene Ontology.
Animal models
Humanized hKLC4 Caenorhabditis elegans Caenorhabditis elegans perturbs The only experimental test of what a truncating KLC4 allele does in a living animal expressing human KLC4. A homozygous truncation is lethal in this background with severe nuclear migration defects, which is direct evidence that the truncation is not tolerated - the question this node otherwise answers only by structural prediction.
Downstream
Impaired Kinesin-1 Cargo Delivery in Developing Neurons
Show evidence (2 references)
PMID:37565267 SUPPORT Computational
"Truncations in KLC4 after either 277 or 369 residues are predicted to disrupt the TPR domain, which mediates the interaction between kinesin and the cargo adaptor (Pernigo et al., 2013; Zhu et al., 2012), suggesting that both KLC4 variants should produce similar pathologies."
The domain-level prediction, graded COMPUTATIONAL because it is inferred from the truncation position and published structures rather than assayed. It is also the sentence that ties the recessive early-childhood allele and the dominant late-onset allele to one molecular lesion.
PMID:36222498 SUPPORT Other
"KLCs are known to mediate binding between the kinesin motor and cellular cargos, and also to activate the motor by releasing KHC autoinhibition"
What the lost domain does. Graded OTHER because the sentence is this paper's summary of established structural and biochemical work rather than a result it reports.
Impaired Kinesin-1 Cargo Delivery in Developing Neurons
Kinesin-1 carries mitochondria, synaptic vesicle precursors, endosomes, lysosomes and RNA granules along microtubules, and the light chain is what makes that transport selective. In a klc4 mutant, endosomal transport and microtubule dynamics are both altered. The specificity of the defect is the notable part. Losing KLC4 does not stop transport in general - mutant axons grow faster than wild type - so the lesion is in which cargo reaches which compartment rather than in how much cargo moves.
sensory neuron CL:0000101 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves sensory neuron (CL:0000101). CL:0000101 is a cell type from the Cell Ontology.
anterograde axonal transport GO:0008089 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves dysregulated anterograde axonal transport (GO:0008089). GO:0008089 is a biological process from the Gene Ontology. ↕ DYSREGULATED
Downstream
Defective Axon Branch Stabilisation and Arbor Patterning
Show evidence (2 references)
PMID:36222498 SUPPORT Model Organism
"Using live imaging approaches in klc4 mutant zebrafish, we show that KLC4 is required for stabilization of nascent axon branches, proper microtubule (MT) dynamics, and endosomal transport."
The three cell-biological requirements measured directly in a klc4 mutant animal.
PMID:36222498 SUPPORT Model Organism
"Klc4 mutant neurons do not have a general growth defect, in that their axons grow faster than wild type axons. In addition, klc4 mutants are adult viable and show no signs of early neurodegeneration."
The control that makes this a specificity defect rather than a transport failure - and, in its second sentence, the observation that sits least comfortably with the word "neurodegeneration" in this disease's name.
Defective Axon Branch Stabilisation and Arbor Patterning
Without KLC4, nascent sensory axon branches fail to stabilise and peripheral axons lose the contact repulsion that normally keeps neighbouring arbors from overlapping - they fasciculate instead, which is how central rather than peripheral axons behave. The result is a sensory field that is innervated in the wrong pattern rather than not innervated at all, and it implies KLC4 helps establish the molecular difference between a neuron's central and peripheral axons. Every measurement behind this node is from zebrafish. Nothing equivalent has been looked at in a patient.
sensory neuron CL:0000101 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves sensory neuron (CL:0000101). CL:0000101 is a cell type from the Cell Ontology.
axon guidance GO:0007411 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal axon guidance (GO:0007411). GO:0007411 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Animal models
klc4 mutant zebrafish Zebrafish recapitulates This node is not a human observation that the fish corroborates - it is the experiment. Axon branch dynamics and arbor tiling cannot be measured in a patient, and no neuropathology from an affected person has been published, so every claim in the node comes from this line.
Downstream
Disordered Patterning Across Multiple Neural Systems
Show evidence (3 references)
PMID:36222498 SUPPORT Model Organism
"Our work implicates one such subunit, KLC4, as an essential regulator of axon branching and arborization pattern of sensory neurons during development."
The paper's central claim about what KLC4 is for.
PMID:36222498 SUPPORT Model Organism
"Furthermore, KLC4 is required for proper tiling of peripheral axon arbors: in klc4 mutants, peripheral axons showed abnormal fasciculation, a behavior characteristic of central axons."
The tiling defect, and the detail that gives it mechanistic meaning: peripheral axons start behaving like central ones, so the lost function is compartment identity rather than growth.
PMID:36222498 SUPPORT Model Organism
"Finally, we find that klc4 mutant larva are hypersensitive to touch and adults show anxiety-like behavior in a novel tank test, implicating klc4 as a new gene involved in stress response circuits."
That the mispatterned arbor has a functional consequence at the level of behaviour, which is what makes the patterning defect more than a morphological curiosity.
Disordered Patterning Across Multiple Neural Systems
The organism-level step, and the weakest link in the chain. In zebrafish, klc4 is expressed early and in diverse neural populations of both the central and peripheral nervous system, so a patterning defect in its absence would be expected to affect several systems at once - which is what the patients have. The zebrafish authors read the human disease that way explicitly, as a disorder of developmental patterning. What is missing is everything between a mispatterned sensory arbor in a fish embryo and a child who loses vision, hearing, walking and cognition. No neuropathology, imaging correlate, nerve conduction study or retinal study from an affected person has been published in a source that can be read, so the edge into this node carries INDIRECT_UNKNOWN_INTERMEDIATES and means it.
Downstream
Progressive Complicated Spastic Paraplegia
Visual Impairment
Hearing Impairment
Cognitive Impairment
Show evidence (3 references)
PMID:36222498 SUPPORT Model Organism
"Our results also give insight into mechanisms of the human disease caused by KLC4 mutation, which may be caused by defects in developmental patterning."
The authors' own bridge from their fish to the human disease, hedged with "may be" - which is the hedge this node preserves rather than removing.
PMID:36222498 SUPPORT Other
"Multiple neural systems are affected in the human disease caused by KLC4 mutation; patients show defects in vision, hearing, movement and cognition (Bayrakli et al., 2015)."
The multisystem character of the human phenotype, and the only quotable statement of it outside the paywalled primary report. Graded OTHER because it is this paper's summary of the clinical literature rather than an observation it made.
PMID:36222498 SUPPORT INDIRECT Model Organism
"The early expression of klc4 in diverse neural populations in both the central and peripheral nervous system suggests it has functions in neural development."
The expression pattern that makes a multisystem consequence expected rather than surprising. Indirect with respect to the human disease because it is measured in zebrafish; no human KLC4 expression study has been published.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for KLC4-Related Early-Childhood-Onset Neurodegeneration Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

4
Ear 1
Hearing Impairment HP:0000365 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hearing impairment (HP:0000365). HP:0000365 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:36222498 SUPPORT Other
"Multiple neural systems are affected in the human disease caused by KLC4 mutation; patients show defects in vision, hearing, movement and cognition (Bayrakli et al., 2015)."
The auditory involvement, at the level of specificity the quotable literature supports.
Eye 1
Visual Impairment HP:0000505 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Visual impairment (HP:0000505). HP:0000505 is a phenotype from the Human Phenotype Ontology.
If the 2015 paper's full text becomes available, this record should be re-examined against it and, if retinitis pigmentosa is documented, rebound to HP:0000510 and split from the general visual record. See the discussion `klc4_disease_name_outruns_its_published_phenotype`.
Show evidence (1 reference)
PMID:36222498 SUPPORT Other
"Multiple neural systems are affected in the human disease caused by KLC4 mutation; patients show defects in vision, hearing, movement and cognition (Bayrakli et al., 2015)."
The visual involvement, at the level of specificity the quotable literature supports. Graded OTHER because it summarises the clinical report rather than reporting new observations.
Musculoskeletal 1
Progressive Complicated Spastic Paraplegia Progressive spastic paraplegia HP:0007020 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Progressive complicated spastic paraplegia, annotated with Progressive spastic paraplegia (HP:0007020). HP:0007020 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:26423925 SUPPORT Human Clinical
"Three patients from the same family shared common features of progressive complicated spastic paraplegia."
The entire published clinical description of this disease's core phenotype, in the abstract of its only clinical report.
PMID:36222498 SUPPORT Other
"Mutation of KLC4 in humans causes a type of hereditary spastic paraplegia (HSP) that manifests in early childhood (Bayrakli et al., 2015), indicating essential developmental functions."
The age of onset, which the primary abstract does not give. Graded OTHER because it is a later paper's summary of the clinical report.
Nervous System 1
Cognitive Impairment HP:0100543 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cognitive impairment (HP:0100543). HP:0100543 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:36222498 SUPPORT Other
"Multiple neural systems are affected in the human disease caused by KLC4 mutation; patients show defects in vision, hearing, movement and cognition (Bayrakli et al., 2015)."
The cognitive involvement, at the level of specificity the quotable literature supports.
🧬

Genetic Associations

1
KLC4
Gene: KLC4 hgnc:21624 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is KLC4 (hgnc:21624). hgnc:21624 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Show evidence (2 references)
PMID:26423925 SUPPORT Human Clinical
"The association of a KLC4 mutation with spastic paraplegia identifies a new locus for the disease."
The gene-disease claim as its discoverers stated it - a new locus, from one family, on the strength of homozygosity mapping and segregation.
PMID:36222498 SUPPORT Other
"Mutations in human klc2 can cause SPOAN syndrome, which is characterized by progressive spastic paraplegia, optic atrophy and neuropathy with onset in infancy"
The paralogue's disease, which is the closest thing to a positive control for this gene-disease relationship: a different kinesin light chain producing a strikingly similar spastic-paraplegia-plus-sensory phenotype.
💊

Medical Actions

1
Genetic Counselling
Action: genetic counselingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is genetic counseling (NCIT:C15240). NCIT:C15240 is a clinical intervention from the NCI Thesaurus. Ontology label: Genetic Counseling NCIT:C15240
Platform: Other
Recessive counselling with a 25 percent recurrence risk for a carrier couple, and consanguinity to discuss in a family where it is the reason the allele became homozygous. Two things specific to this disease belong in the conversation: the gene-phenotype relationship is flagged by OMIM as unconfirmed, so a KLC4 result should be presented as probable rather than settled; and unaffected heterozygous relatives in the reported family had no symptoms, which is the reassurance carrier testing can offer.
Show evidence (1 reference)
PMID:26423925 SUPPORT Human Clinical
"Meanwhile, the unaffected parents and two siblings were heterozygous and one sibling was homozygous wild type."
The carrier state in this family, which is the concrete fact counselling turns on: four heterozygous relatives, none affected.
🔬

Diagnosis

1
Homozygosity mapping with exome sequencing in a consanguineous pedigree
The diagnosis was reached the way recessive diseases in consanguineous families usually are: clinical phenotyping, then homozygosity mapping to find shared runs of homozygosity, then whole-exome sequencing within them. The interpretive caution is the same one that applies to any gene at unconfirmed validity - a KLC4 variant found on a panel or exome in a child with complicated spastic paraplegia is a candidate to pursue with segregation testing, not a finished diagnosis, and OMIM's own qualifier on this gene-phenotype mapping should be read alongside it.
Show evidence (1 reference)
PMID:26423925 SUPPORT Human Clinical
"Clinical phenotyping of one consanguineous family followed by combined homozygosity mapping and whole-exome sequencing analysis."
The diagnostic route, stated as the paper's own methods summary.
📊

Prevalence

1
Worldwide
Cases In Literature Ultra Rare
Three affected siblings in one consanguineous family, reported once, in 2015. No second published family in the eleven years since. No prevalence or incidence estimate exists, so ULTRA_RARE is a qualitative band and no rate_per_100000 is recorded. The absence of a second family is part of why OMIM flags the gene-phenotype mapping as unconfirmed.
Show evidence (1 reference)
PMID:26423925 SUPPORT Human Clinical
"Three patients from the same family shared common features of progressive complicated spastic paraplegia."
The published case count, which is also the current case count.
🐁

Animal Models

2
klc4 mutant zebrafish
The principal in vivo model, and the source of essentially all of this entry's cell biology. Live imaging in klc4 mutant embryos shows that KLC4 is required for stabilising nascent sensory axon branches, for normal microtubule dynamics and endosomal transport, and for the contact repulsion that keeps peripheral arbors tiled rather than fasciculated. Mutant larvae are hypersensitive to touch and mutant adults show anxiety-like behaviour. It is also the model that complicates the disease's name: these fish are adult viable and show no signs of early neurodegeneration.
Species
Zebrafish
Genotype
klc4 uw314 (nonsense mutation, homozygous)
Genes
KLC4 hgnc:21624 HUGO Gene Nomenclature Committee (hgnc) Relation: this experimental model concerns this gene This experimental model concerns KLC4 (hgnc:21624). hgnc:21624 is a gene from the HUGO Gene Nomenclature Committee.
Publication
PMID:36222498
Pathograph links
Defective Axon Branch Stabilisation and Arbor Patterning recapitulates fidelity: moderate This node is not a human observation that the fish corroborates - it is the experiment. Axon branch dynamics and arbor tiling cannot be measured in a patient, and no neuropathology from an affected person has been published, so every claim in the node comes from this line.
Limitations: Two gaps. The fish is a whole-animal nonsense mutant of a single klc4 gene, while the human patients are homozygous for a truncation in one of four light chains whose paralogues are also expressed in neurons - so redundancy differs between the species and nothing establishes that a human KLC4 truncation produces the same cellular defect. And the measurements are in embryonic Rohon-Beard sensory neurons, a cell type with no direct human counterpart, whereas the human phenotype is dominated by corticospinal involvement that this model does not address at all. Fidelity is MODERATE rather than HIGH for that reason.
Readouts
Nascent axon branch stabilization
Direction: DECREASED
Interpretation: New peripheral sensory axon branches fail to be maintained in the mutant, which is the primary morphological defect the model shows.
Show evidence (1 reference)
PMID:36222498 SUPPORT Model Organism
"Using live imaging approaches in klc4 mutant zebrafish, we show that KLC4 is required for stabilization of nascent axon branches, proper microtubule (MT) dynamics, and endosomal transport."
The live-imaging measurement behind this readout.
Peripheral axon contact repulsion and arbor tiling
Direction: ALTERED
Interpretation: Peripheral axons fasciculate instead of repelling on contact, so arbors overlap rather than tile - a change in axon identity rather than in growth capacity.
Show evidence (1 reference)
PMID:36222498 SUPPORT Model Organism
"Furthermore, KLC4 is required for proper tiling of peripheral axon arbors: in klc4 mutants, peripheral axons showed abnormal fasciculation, a behavior characteristic of central axons."
The tiling and fasciculation measurement behind this readout.
Touch sensitivity and adult anxiety-like behaviour
Direction: INCREASED
Interpretation: The mispatterned sensory arbor has a behavioural consequence: larvae over-respond to touch, and adults show anxiety-like behaviour in a novel tank.
Show evidence (1 reference)
PMID:36222498 SUPPORT Model Organism
"Finally, we find that klc4 mutant larva are hypersensitive to touch and adults show anxiety-like behavior in a novel tank test, implicating klc4 as a new gene involved in stress response circuits."
The behavioural measurements behind this readout.
Show evidence (1 reference)
PMID:36222498 SUPPORT Model Organism
"Our work implicates one such subunit, KLC4, as an essential regulator of axon branching and arborization pattern of sensory neurons during development."
Why this line is informative for a node about axon branching and arbor pattern.
Humanized hKLC4 Caenorhabditis elegans
A humanised worm built to test KLC4 variants of uncertain significance: the endogenous klc-2 gene was replaced with human KLC4, which retained most of klc-2's function, and five hKLC4 variants were then introduced into that background. The clinical variant caused early lethality with nuclear migration defects when homozygous and a weak defect when heterozygous. Important scope limit: the "clinical variant" here is the *heterozygous, late-onset* frameshift at residue 369 from an Undiagnosed Diseases Network proband, not the homozygous exon-6 deletion of the family this entry curates. The model is included because both truncations are predicted to remove the same cargo-binding domain, so it speaks to whether losing that domain is deleterious - not to this disease's allele.
Species
Caenorhabditis elegans
Genotype
klc-2 replaced by human KLC4 (hKLC4), with hKLC4 variants introduced
Genes
KLC4 hgnc:21624 HUGO Gene Nomenclature Committee (hgnc) Relation: this experimental model concerns this gene This experimental model concerns KLC4 (hgnc:21624). hgnc:21624 is a gene from the HUGO Gene Nomenclature Committee.
Publication
PMID:37565267
Pathograph links
Loss of the KLC4 Cargo-Binding TPR Domain perturbs fidelity: low The only experimental test of what a truncating KLC4 allele does in a living animal expressing human KLC4. A homozygous truncation is lethal in this background with severe nuclear migration defects, which is direct evidence that the truncation is not tolerated - the question this node otherwise answers only by structural prediction.
Limitations: The allele is the wrong one: a residue-369 frameshift from a heterozygous late-onset patient, not the residue-277 truncation of this recessive childhood disease. The readout is also the wrong one: nuclear migration is a klc-2 function in the worm with no established counterpart in this disease's phenotype. And the paper notes that a dominant-negative effect of the truncated protein could not be reproduced in this system at all, because the transcript is likely subject to nonsense-mediated decay. Fidelity is LOW; this establishes that the domain matters, and nothing about the disease.
Readouts
Nuclear migration in humanized hKLC4 worms carrying the clinical variant
Direction: ALTERED
Interpretation: Homozygous clinical variant animals show significant nuclear migration defects and early lethality; heterozygotes show a weak defect.
Show evidence (1 reference)
PMID:37565267 SUPPORT Model Organism
"The clinical variant led to early lethality, with significant defects in nuclear migration when homozygous and a weak nuclear migration defect when heterozygous, possibly correlating with the clinical finding of late-onset HSP when the proband was heterozygous."
The measurement behind this readout, with the authors' own hedge on its clinical correlation.
Show evidence (1 reference)
PMID:37565267 SUPPORT Model Organism
"We created a humanized Caenorhabditis elegans model in which klc-2 was replaced by human KLC4 (referred to as hKLC4) and assessed the extent to which hKLC4 retained function in the worm."
What makes this line informative for a node about human KLC4 domain loss: it is human KLC4 protein being tested, not a worm orthologue.
{ }

Source YAML

click to show 
name: KLC4-Related Early-Childhood-Onset Neurodegeneration
category: Mendelian
creation_date: "2026-09-04T00:00:00Z"
synonyms:
- CONDRHN
- early-childhood-onset neurodegeneration with retinitis pigmentosa, sensorineural hearing loss, and demyelinating peripheral neuropathy
- KLC4-related complicated hereditary spastic paraplegia
description: >-
  A childhood-onset multisystem neurodegenerative disorder caused by biallelic truncating
  KLC4 variants, known from a single consanguineous family. KLC4 encodes kinesin light chain
  4, one of the four cargo-binding light-chain subunits of the kinesin-1 motor, and the
  reported allele - a 19-base-pair deletion in exon 6 - introduces a stop codon that removes
  the tetratricopeptide repeats through which the light chain binds cargo adaptors.

  Two things about this entry's scope need stating before anything else, because both are
  unusual.

  First, the disease's own name is more specific than its published clinical description.
  MONDO and OMIM call it "early-childhood-onset neurodegeneration with retinitis pigmentosa,
  sensorineural hearing loss, and demyelinating peripheral neuropathy", and MedGen
  attributes that description to the single 2015 report. That report's abstract describes
  the three affected siblings only as having "progressive complicated spastic paraplegia";
  its full text is behind a paywall and cannot be quoted. The nearest independently
  published statement of the phenotype is a later paper's summary - patients show defects
  in vision, hearing, movement and cognition - and that is the level at which the phenotype
  records below are curated. Retinitis pigmentosa, the sensorineural character of the
  hearing loss, and the demyelinating character of the neuropathy are all in the disease's
  name and none is supported by a source this entry can quote.

  Second, OMIM itself treats the gene-phenotype relationship as unconfirmed. NCBI's
  `mim2gene_medgen` maps MIM 621129 to KLC4 with the comment `question`, which the file's
  own documentation defines as "A question mark, '?', before the disease name indicates an
  unconfirmed or possibly spurious mapping". One family, one allele, and no replication in
  the eleven years since. ClinVar does hold a second KLC4 allele classified against this
  disease concept - `NM_201521.3:c.1164T>A` (p.Cys388Ter), likely pathogenic - but a PubMed
  search for KLC4 turned up no publication describing that patient, so it does not enter
  this entry as evidence.

  What is well supported is the cell biology. KLC4 is expressed broadly in developing
  central and peripheral neurons, and a zebrafish klc4 mutant shows that it is required for
  stabilising nascent axon branches, for normal microtubule dynamics and endosomal
  transport, and for the contact repulsion that lets peripheral sensory arbors tile. The
  fish's authors read the human disease as a disorder of developmental patterning rather
  than of bulk cargo transport - which fits a multisystem sensory and motor phenotype, and
  sits awkwardly with the word "neurodegeneration" in the disease name, since the fish
  mutant is adult viable with no early degeneration at all.

  A separate KLC4 story should not be merged into this one. A man reported in 2023 through
  the Undiagnosed Diseases Network had slowly progressive myelopathy and neuropathy from
  around age fifty, carrying a *heterozygous* frameshift at residue 369 - a different
  allele, a different inheritance mode, and a different age of onset by half a century.
  Both truncations are predicted to remove the same cargo-binding domain, which is why the
  two are discussed together in the literature, but they are not the same disease and this
  entry does not curate the late-onset case as one.
disease_term:
  preferred_term: early-childhood-onset neurodegeneration with retinitis pigmentosa, sensorineural hearing loss, and demyelinating peripheral neuropathy
  term:
    id: MONDO:0700288
    label: early-childhood-onset neurodegeneration with retinitis pigmentosa, sensorineural hearing loss, and demyelinating peripheral neuropathy
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0700288
      label: early-childhood-onset neurodegeneration with retinitis pigmentosa, sensorineural hearing loss, and demyelinating peripheral neuropathy
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
references:
- reference: PMID:26423925
  title: "Hereditary spastic paraplegia with recessive trait caused by mutation in KLC4 gene."
- reference: PMID:36222498
  title: "KLC4 shapes axon arbors during development and mediates adult behavior."
- reference: PMID:37565267
  title: "A humanized Caenorhabditis elegans model of hereditary spastic paraplegia-associated variants in KLC4."
inheritance:
- name: Autosomal recessive
  description: >-
    A homozygous KLC4 deletion in three affected siblings of one consanguineous family, with
    both unaffected parents and two unaffected siblings heterozygous and a third unaffected
    sibling homozygous wild type. That is complete segregation within the family, and the
    unaffected heterozygotes are what makes the mode recessive rather than dominant with
    reduced penetrance. Only one family has been reported, so nothing can be said about
    penetrance, expressivity or de novo rate.
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:26423925
    reference_title: "Hereditary spastic paraplegia with recessive trait caused by mutation in KLC4 gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Meanwhile, the unaffected parents and two siblings were heterozygous and one sibling was homozygous wild type."
    explanation: >-
      The segregation result. Carrier parents and an unaffected homozygous-wild-type sibling
      together establish recessive inheritance in this pedigree.
  - reference: PMID:37565267
    reference_title: "A humanized Caenorhabditis elegans model of hereditary spastic paraplegia-associated variants in KLC4."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "An additional family was previously reported where a premature stop codon after residue 277 of KLC4 caused HSP in an autosomal-recessive manner; heterozygous family members did not have any symptoms (Bayrakli et al., 2015)."
    explanation: >-
      An independent group's reading of the same pedigree, which matters here because it is
      the sentence that separates this recessive entity from the heterozygous late-onset case
      the same paper reports. Graded OTHER because it summarises prior work rather than
      reporting a new observation.
pathophysiology:
- name: KLC4 Homozygous Truncating Deletion
  description: >-
    A homozygous 19-base-pair deletion in exon 6 of KLC4, c.853_871del19, found by
    homozygosity mapping followed by whole-exome sequencing in a consanguineous family. The
    deletion generates a stop codon, so both the transcript and the protein are truncated.
    It is the only allele reported in a published patient with this disease.
  biological_scale: MOLECULAR
  genes:
  - preferred_term: KLC4
    term:
      id: hgnc:21624
      label: KLC4
  downstream:
  - target: Loss of the KLC4 Cargo-Binding TPR Domain
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:26423925
    reference_title: "Hereditary spastic paraplegia with recessive trait caused by mutation in KLC4 gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Whole-exome sequencing revealed a homozygous mutation (c.853_871del19) in the gene coding the kinesin light chain 4 protein (KLC4)."
    explanation: The allele, and the gene it identifies.
  - reference: PMID:26423925
    reference_title: "Hereditary spastic paraplegia with recessive trait caused by mutation in KLC4 gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The 19 bp deletion in exon 6 generates a stop codon and thus a truncated messenger RNA and protein."
    explanation: >-
      The molecular consequence, stated at both the transcript and the protein level. The
      truncated transcript matters because nonsense-mediated decay may remove it altogether,
      which is the difference between a null and a dominant-negative allele.
- name: Loss of the KLC4 Cargo-Binding TPR Domain
  description: >-
    The kinesin light chains carry six tetratricopeptide repeats that bind cargo adaptor
    proteins, and they also activate the motor by relieving autoinhibition of the kinesin
    heavy chain. A stop codon after residue 277 removes those repeats. This is a prediction
    from the position of the truncation rather than a measurement: no patient material has
    been assayed for KLC4 protein, cargo binding or motor activity.
  biological_scale: MOLECULAR
  cellular_components:
  - preferred_term: kinesin I complex
    term:
      id: GO:0016938
      label: kinesin I complex
  downstream:
  - target: Impaired Kinesin-1 Cargo Delivery in Developing Neurons
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:37565267
    reference_title: "A humanized Caenorhabditis elegans model of hereditary spastic paraplegia-associated variants in KLC4."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "Truncations in KLC4 after either 277 or 369 residues are predicted to disrupt the TPR domain, which mediates the interaction between kinesin and the cargo adaptor (Pernigo et al., 2013; Zhu et al., 2012), suggesting that both KLC4 variants should produce similar pathologies."
    explanation: >-
      The domain-level prediction, graded COMPUTATIONAL because it is inferred from the
      truncation position and published structures rather than assayed. It is also the
      sentence that ties the recessive early-childhood allele and the dominant late-onset
      allele to one molecular lesion.
  - reference: PMID:36222498
    reference_title: "KLC4 shapes axon arbors during development and mediates adult behavior."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "KLCs are known to mediate binding between the kinesin motor and cellular cargos, and also to activate the motor by releasing KHC autoinhibition"
    explanation: >-
      What the lost domain does. Graded OTHER because the sentence is this paper's summary of
      established structural and biochemical work rather than a result it reports.
- name: Impaired Kinesin-1 Cargo Delivery in Developing Neurons
  description: >-
    Kinesin-1 carries mitochondria, synaptic vesicle precursors, endosomes, lysosomes and RNA
    granules along microtubules, and the light chain is what makes that transport selective.
    In a klc4 mutant, endosomal transport and microtubule dynamics are both altered.

    The specificity of the defect is the notable part. Losing KLC4 does not stop transport
    in general - mutant axons grow faster than wild type - so the lesion is in which cargo
    reaches which compartment rather than in how much cargo moves.
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: sensory neuron
    term:
      id: CL:0000101
      label: sensory neuron
  biological_processes:
  - preferred_term: anterograde axonal transport
    term:
      id: GO:0008089
      label: anterograde axonal transport
    modifier: DYSREGULATED
  downstream:
  - target: Defective Axon Branch Stabilisation and Arbor Patterning
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:36222498
    reference_title: "KLC4 shapes axon arbors during development and mediates adult behavior."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Using live imaging approaches in klc4 mutant zebrafish, we show that KLC4 is required for stabilization of nascent axon branches, proper microtubule (MT) dynamics, and endosomal transport."
    explanation: The three cell-biological requirements measured directly in a klc4 mutant animal.
  - reference: PMID:36222498
    reference_title: "KLC4 shapes axon arbors during development and mediates adult behavior."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Klc4 mutant neurons do not have a general growth defect, in that their axons grow faster than wild type axons. In addition, klc4 mutants are adult viable and show no signs of early neurodegeneration."
    explanation: >-
      The control that makes this a specificity defect rather than a transport failure -
      and, in its second sentence, the observation that sits least comfortably with the word
      "neurodegeneration" in this disease's name.
- name: Defective Axon Branch Stabilisation and Arbor Patterning
  description: >-
    Without KLC4, nascent sensory axon branches fail to stabilise and peripheral axons lose
    the contact repulsion that normally keeps neighbouring arbors from overlapping - they
    fasciculate instead, which is how central rather than peripheral axons behave. The result
    is a sensory field that is innervated in the wrong pattern rather than not innervated at
    all, and it implies KLC4 helps establish the molecular difference between a neuron's
    central and peripheral axons.

    Every measurement behind this node is from zebrafish. Nothing equivalent has been looked
    at in a patient.
  biological_scale: CELLULAR
  biological_processes:
  - preferred_term: axon guidance
    term:
      id: GO:0007411
      label: axon guidance
    modifier: ABNORMAL
  cell_types:
  - preferred_term: sensory neuron
    term:
      id: CL:0000101
      label: sensory neuron
  downstream:
  - target: Disordered Patterning Across Multiple Neural Systems
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:36222498
    reference_title: "KLC4 shapes axon arbors during development and mediates adult behavior."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Our work implicates one such subunit, KLC4, as an essential regulator of axon branching and arborization pattern of sensory neurons during development."
    explanation: The paper's central claim about what KLC4 is for.
  - reference: PMID:36222498
    reference_title: "KLC4 shapes axon arbors during development and mediates adult behavior."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Furthermore, KLC4 is required for proper tiling of peripheral axon arbors: in klc4 mutants, peripheral axons showed abnormal fasciculation, a behavior characteristic of central axons."
    explanation: >-
      The tiling defect, and the detail that gives it mechanistic meaning: peripheral axons
      start behaving like central ones, so the lost function is compartment identity rather
      than growth.
  - reference: PMID:36222498
    reference_title: "KLC4 shapes axon arbors during development and mediates adult behavior."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Finally, we find that klc4 mutant larva are hypersensitive to touch and adults show anxiety-like behavior in a novel tank test, implicating klc4 as a new gene involved in stress response circuits."
    explanation: >-
      That the mispatterned arbor has a functional consequence at the level of behaviour,
      which is what makes the patterning defect more than a morphological curiosity.
- name: Disordered Patterning Across Multiple Neural Systems
  description: >-
    The organism-level step, and the weakest link in the chain. In zebrafish, klc4 is
    expressed early and in diverse neural populations of both the central and peripheral
    nervous system, so a patterning defect in its absence would be expected to affect several
    systems at once - which is what the patients have.
    The zebrafish authors read the human disease that way explicitly, as a disorder of
    developmental patterning.

    What is missing is everything between a mispatterned sensory arbor in a fish embryo and
    a child who loses vision, hearing, walking and cognition. No neuropathology, imaging
    correlate, nerve conduction study or retinal study from an affected person has been
    published in a source that can be read, so the edge into this node carries
    INDIRECT_UNKNOWN_INTERMEDIATES and means it.
  biological_scale: ORGANISM
  downstream:
  - target: Progressive Complicated Spastic Paraplegia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Visual Impairment
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Hearing Impairment
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Cognitive Impairment
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:36222498
    reference_title: "KLC4 shapes axon arbors during development and mediates adult behavior."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Our results also give insight into mechanisms of the human disease caused by KLC4 mutation, which may be caused by defects in developmental patterning."
    explanation: >-
      The authors' own bridge from their fish to the human disease, hedged with "may be" -
      which is the hedge this node preserves rather than removing.
  - reference: PMID:36222498
    reference_title: "KLC4 shapes axon arbors during development and mediates adult behavior."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Multiple neural systems are affected in the human disease caused by KLC4 mutation; patients show defects in vision, hearing, movement and cognition (Bayrakli et al., 2015)."
    explanation: >-
      The multisystem character of the human phenotype, and the only quotable statement of it
      outside the paywalled primary report. Graded OTHER because it is this paper's summary
      of the clinical literature rather than an observation it made.
  - reference: PMID:36222498
    reference_title: "KLC4 shapes axon arbors during development and mediates adult behavior."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    directness: INDIRECT
    snippet: "The early expression of klc4 in diverse neural populations in both the central and peripheral nervous system suggests it has functions in neural development."
    explanation: >-
      The expression pattern that makes a multisystem consequence expected rather than
      surprising. Indirect with respect to the human disease because it is measured in
      zebrafish; no human KLC4 expression study has been published.
phenotypes:
- name: Progressive Complicated Spastic Paraplegia
  category: Neurological
  description: >-
    Progressive spastic paraplegia with additional neurological features - "complicated" in
    the hereditary spastic paraplegia sense, meaning spasticity plus involvement beyond the
    corticospinal tracts. All three affected siblings shared it. Onset is in early childhood.

    No age at onset, examination finding, gait description, imaging result or nerve
    conduction study is available in a quotable source, so none is curated. Three siblings in
    one family is too small a denominator for a frequency band and none is recorded.
  phenotype_term:
    preferred_term: Progressive complicated spastic paraplegia
    term:
      id: HP:0007020
      label: Progressive spastic paraplegia
  evidence:
  - reference: PMID:26423925
    reference_title: "Hereditary spastic paraplegia with recessive trait caused by mutation in KLC4 gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Three patients from the same family shared common features of progressive complicated spastic paraplegia."
    explanation: >-
      The entire published clinical description of this disease's core phenotype, in the
      abstract of its only clinical report.
  - reference: PMID:36222498
    reference_title: "KLC4 shapes axon arbors during development and mediates adult behavior."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Mutation of KLC4 in humans causes a type of hereditary spastic paraplegia (HSP) that manifests in early childhood (Bayrakli et al., 2015), indicating essential developmental functions."
    explanation: >-
      The age of onset, which the primary abstract does not give. Graded OTHER because it is
      a later paper's summary of the clinical report.
- name: Visual Impairment
  category: Ophthalmological
  description: >-
    Impaired vision. Curated at this level deliberately: the disease's MONDO and OMIM name
    specifies retinitis pigmentosa, but no source that can be quoted describes a retinal
    finding in these patients, and binding a retinal dystrophy term would assert an
    examination result this entry cannot show.
  phenotype_term:
    preferred_term: Visual impairment
    term:
      id: HP:0000505
      label: Visual impairment
  notes: >-
    If the 2015 paper's full text becomes available, this record should be re-examined
    against it and, if retinitis pigmentosa is documented, rebound to HP:0000510 and split
    from the general visual record. See the discussion
    `klc4_disease_name_outruns_its_published_phenotype`.
  evidence:
  - reference: PMID:36222498
    reference_title: "KLC4 shapes axon arbors during development and mediates adult behavior."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Multiple neural systems are affected in the human disease caused by KLC4 mutation; patients show defects in vision, hearing, movement and cognition (Bayrakli et al., 2015)."
    explanation: >-
      The visual involvement, at the level of specificity the quotable literature supports.
      Graded OTHER because it summarises the clinical report rather than reporting new
      observations.
- name: Hearing Impairment
  category: Auditory
  description: >-
    Impaired hearing. As with vision, the disease's name specifies sensorineural hearing
    loss and no quotable source establishes the sensorineural character, so the record is
    bound to the general term.

    Worth noting for a reader who wonders whether the sensorineural attribution is
    plausible: the paralogous light chain KLC2 does produce hearing loss with cochlear hair
    cell loss in mouse, so a cochlear lesion would not be surprising for a kinesin light
    chain. That is a reason to look, not evidence about these patients.
  phenotype_term:
    preferred_term: Hearing impairment
    term:
      id: HP:0000365
      label: Hearing impairment
  evidence:
  - reference: PMID:36222498
    reference_title: "KLC4 shapes axon arbors during development and mediates adult behavior."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Multiple neural systems are affected in the human disease caused by KLC4 mutation; patients show defects in vision, hearing, movement and cognition (Bayrakli et al., 2015)."
    explanation: >-
      The auditory involvement, at the level of specificity the quotable literature supports.
- name: Cognitive Impairment
  category: Neurological
  description: >-
    Impaired cognition. No developmental assessment, IQ measure or trajectory is available in
    a quotable source, so nothing is said about severity or whether the impairment is
    developmental or acquired.
  phenotype_term:
    preferred_term: Cognitive impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
  evidence:
  - reference: PMID:36222498
    reference_title: "KLC4 shapes axon arbors during development and mediates adult behavior."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Multiple neural systems are affected in the human disease caused by KLC4 mutation; patients show defects in vision, hearing, movement and cognition (Bayrakli et al., 2015)."
    explanation: >-
      The cognitive involvement, at the level of specificity the quotable literature supports.
genetic:
- name: KLC4
  notes: >-
    KLC4 encodes kinesin light chain 4, one of four vertebrate kinesin light chains. Three of
    them - KLC1, KLC2 and KLC4 - are expressed in the nervous system, and the evidence is
    that they divide the work rather than substituting for one another: each has distinct
    cargo-adaptor affinities and distinct loss-of-function phenotypes. In zebrafish, klc4 is
    expressed early and in diverse neural populations of both the central and peripheral
    nervous system; no equivalent human expression study has been published.

    One published disease allele exists: c.853_871del19 in exon 6, homozygous, in one
    consanguineous family. ClinVar holds a second allele classified against this disease
    concept, NM_201521.3:c.1164T>A (p.Cys388Ter), as likely pathogenic. A PubMed search
    for KLC4 and for "kinesin light chain 4" returned no clinical report beyond the two
    discussed here, so that allele is not used as evidence.

    The gene-phenotype relationship is not settled. NCBI's `mim2gene_medgen` maps MIM 621129
    to KLC4 with the qualifier `question`, which that file's documentation defines as a
    question mark before the disease name in OMIM, indicating an unconfirmed or possibly
    spurious mapping. KLC4 has no ClinGen gene-disease validity classification - it does not
    appear in the ClinGen Gene-Disease Validity CSV.

    The sibling gene is worth knowing about when reading this disease. Biallelic KLC2
    variants cause SPOAN syndrome, a progressive spastic paraplegia with optic atrophy and
    neuropathy beginning in infancy, which is close enough to this phenotype that the two
    genes are best understood as a pair.
  relationship_type: CAUSATIVE
  gene_term:
    preferred_term: KLC4
    term:
      id: hgnc:21624
      label: KLC4
  evidence:
  - reference: PMID:26423925
    reference_title: "Hereditary spastic paraplegia with recessive trait caused by mutation in KLC4 gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The association of a KLC4 mutation with spastic paraplegia identifies a new locus for the disease."
    explanation: >-
      The gene-disease claim as its discoverers stated it - a new locus, from one family, on
      the strength of homozygosity mapping and segregation.
  - reference: PMID:36222498
    reference_title: "KLC4 shapes axon arbors during development and mediates adult behavior."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Mutations in human klc2 can cause SPOAN syndrome, which is characterized by progressive spastic paraplegia, optic atrophy and neuropathy with onset in infancy"
    explanation: >-
      The paralogue's disease, which is the closest thing to a positive control for this
      gene-disease relationship: a different kinesin light chain producing a strikingly
      similar spastic-paraplegia-plus-sensory phenotype.
prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >-
    Three affected siblings in one consanguineous family, reported once, in 2015. No second
    published family in the eleven years since. No prevalence or incidence estimate exists,
    so ULTRA_RARE is a qualitative band and no rate_per_100000 is recorded. The absence of a
    second family is part of why OMIM flags the gene-phenotype mapping as unconfirmed.
  evidence:
  - reference: PMID:26423925
    reference_title: "Hereditary spastic paraplegia with recessive trait caused by mutation in KLC4 gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Three patients from the same family shared common features of progressive complicated spastic paraplegia."
    explanation: The published case count, which is also the current case count.
diagnosis:
- name: Homozygosity mapping with exome sequencing in a consanguineous pedigree
  description: >-
    The diagnosis was reached the way recessive diseases in consanguineous families usually
    are: clinical phenotyping, then homozygosity mapping to find shared runs of homozygosity,
    then whole-exome sequencing within them. The interpretive caution is the same one that
    applies to any gene at unconfirmed validity - a KLC4 variant found on a panel or exome in
    a child with complicated spastic paraplegia is a candidate to pursue with segregation
    testing, not a finished diagnosis, and OMIM's own qualifier on this gene-phenotype
    mapping should be read alongside it.
  evidence:
  - reference: PMID:26423925
    reference_title: "Hereditary spastic paraplegia with recessive trait caused by mutation in KLC4 gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical phenotyping of one consanguineous family followed by combined homozygosity mapping and whole-exome sequencing analysis."
    explanation: The diagnostic route, stated as the paper's own methods summary.
treatments:
- name: Genetic Counselling
  description: >-
    Recessive counselling with a 25 percent recurrence risk for a carrier couple, and
    consanguinity to discuss in a family where it is the reason the allele became homozygous.
    Two things specific to this disease belong in the conversation: the gene-phenotype
    relationship is flagged by OMIM as unconfirmed, so a KLC4 result should be presented as
    probable rather than settled; and unaffected heterozygous relatives in the reported
    family had no symptoms, which is the reassurance carrier testing can offer.
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  notes: >-
    No target_mechanisms link is recorded: counselling does not act on a pathograph node and
    every TreatmentEffectEnum value asserts a change to a mechanism.

    This is the only treatment record in the entry because it is the only one that can be
    stated without inventing an experience. No management of any kind is described for any
    affected individual - no physiotherapy, no antispasticity drug, no hearing or visual
    aid, no outcome - and no KLC4-directed therapy or clinical trial exists. Symptomatic
    management of spasticity and sensory impairment is what these children would receive,
    but writing that as a treatment record would state a class-level standard of care as
    though it were something known about this disease.
  evidence:
  - reference: PMID:26423925
    reference_title: "Hereditary spastic paraplegia with recessive trait caused by mutation in KLC4 gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Meanwhile, the unaffected parents and two siblings were heterozygous and one sibling was homozygous wild type."
    explanation: >-
      The carrier state in this family, which is the concrete fact counselling turns on: four
      heterozygous relatives, none affected.
animal_models:
- name: klc4 mutant zebrafish
  species: Zebrafish
  genotype: klc4 uw314 (nonsense mutation, homozygous)
  publication: PMID:36222498
  description: >-
    The principal in vivo model, and the source of essentially all of this entry's cell
    biology. Live imaging in klc4 mutant embryos shows that KLC4 is required for stabilising
    nascent sensory axon branches, for normal microtubule dynamics and endosomal transport,
    and for the contact repulsion that keeps peripheral arbors tiled rather than
    fasciculated. Mutant larvae are hypersensitive to touch and mutant adults show
    anxiety-like behaviour.

    It is also the model that complicates the disease's name: these fish are adult viable
    and show no signs of early neurodegeneration.
  genes:
  - preferred_term: KLC4
    term:
      id: hgnc:21624
      label: KLC4
  modeled_mechanisms:
  - target: Defective Axon Branch Stabilisation and Arbor Patterning
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      This node is not a human observation that the fish corroborates - it is the experiment.
      Axon branch dynamics and arbor tiling cannot be measured in a patient, and no
      neuropathology from an affected person has been published, so every claim in the node
      comes from this line.
    limitations: >-
      Two gaps. The fish is a whole-animal nonsense mutant of a single klc4 gene, while the
      human patients are homozygous for a truncation in one of four light chains whose
      paralogues are also expressed in neurons - so redundancy differs between the species
      and nothing establishes that a human KLC4 truncation produces the same cellular defect.
      And the measurements are in embryonic Rohon-Beard sensory neurons, a cell type with no
      direct human counterpart, whereas the human phenotype is dominated by corticospinal
      involvement that this model does not address at all. Fidelity is MODERATE rather than
      HIGH for that reason.
    readouts:
    - name: Nascent axon branch stabilization
      target: Defective Axon Branch Stabilisation and Arbor Patterning
      direction: DECREASED
      interpretation: >-
        New peripheral sensory axon branches fail to be maintained in the mutant, which is
        the primary morphological defect the model shows.
      evidence:
      - reference: PMID:36222498
        reference_title: "KLC4 shapes axon arbors during development and mediates adult behavior."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "Using live imaging approaches in klc4 mutant zebrafish, we show that KLC4 is required for stabilization of nascent axon branches, proper microtubule (MT) dynamics, and endosomal transport."
        explanation: The live-imaging measurement behind this readout.
    - name: Peripheral axon contact repulsion and arbor tiling
      target: Defective Axon Branch Stabilisation and Arbor Patterning
      direction: ALTERED
      interpretation: >-
        Peripheral axons fasciculate instead of repelling on contact, so arbors overlap
        rather than tile - a change in axon identity rather than in growth capacity.
      evidence:
      - reference: PMID:36222498
        reference_title: "KLC4 shapes axon arbors during development and mediates adult behavior."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "Furthermore, KLC4 is required for proper tiling of peripheral axon arbors: in klc4 mutants, peripheral axons showed abnormal fasciculation, a behavior characteristic of central axons."
        explanation: The tiling and fasciculation measurement behind this readout.
    - name: Touch sensitivity and adult anxiety-like behaviour
      target: Defective Axon Branch Stabilisation and Arbor Patterning
      direction: INCREASED
      interpretation: >-
        The mispatterned sensory arbor has a behavioural consequence: larvae over-respond to
        touch, and adults show anxiety-like behaviour in a novel tank.
      evidence:
      - reference: PMID:36222498
        reference_title: "KLC4 shapes axon arbors during development and mediates adult behavior."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "Finally, we find that klc4 mutant larva are hypersensitive to touch and adults show anxiety-like behavior in a novel tank test, implicating klc4 as a new gene involved in stress response circuits."
        explanation: The behavioural measurements behind this readout.
    evidence:
    - reference: PMID:36222498
      reference_title: "KLC4 shapes axon arbors during development and mediates adult behavior."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Our work implicates one such subunit, KLC4, as an essential regulator of axon branching and arborization pattern of sensory neurons during development."
      explanation: Why this line is informative for a node about axon branching and arbor pattern.
  - target: Progressive Complicated Spastic Paraplegia
    relationship: FAILS_TO_RECAPITULATE
    fidelity: LOW
    description: >-
      The human disease is a childhood-onset progressive neurodegeneration with spastic
      paraplegia. The fish mutant is adult viable, its axons grow faster rather than slower,
      and it shows no signs of early neurodegeneration. Whatever the fish is modelling, it is
      not degeneration.
    limitations: >-
      The mismatch may be real biology or may be species redundancy: zebrafish and human both
      have several kinesin light chains, but nothing establishes that the compensation
      available in a fish is available in a child, and no ageing study of these mutants
      beyond adult viability has been published. Nor has the fish been examined for a
      corticospinal-equivalent phenotype - fish have no corticospinal tract - so the absence
      of paraplegia is partly a statement about the model's anatomy rather than about KLC4.
      Recorded as FAILS_TO_RECAPITULATE because the published phenotypes do not correspond,
      not because degeneration has been excluded as a consequence of KLC4 loss.
    evidence:
    - reference: PMID:36222498
      reference_title: "KLC4 shapes axon arbors during development and mediates adult behavior."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Klc4 mutant neurons do not have a general growth defect, in that their axons grow faster than wild type axons. In addition, klc4 mutants are adult viable and show no signs of early neurodegeneration."
      explanation: >-
        The negative result itself - viability and no early degeneration in the mutant fish.
    - reference: PMID:26423925
      reference_title: "Hereditary spastic paraplegia with recessive trait caused by mutation in KLC4 gene."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Three patients from the same family shared common features of progressive complicated spastic paraplegia."
      explanation: >-
        The human side of the mismatch: a progressive disorder, which is what the fish does
        not reproduce.
- name: Humanized hKLC4 Caenorhabditis elegans
  species: Caenorhabditis elegans
  genotype: klc-2 replaced by human KLC4 (hKLC4), with hKLC4 variants introduced
  publication: PMID:37565267
  description: >-
    A humanised worm built to test KLC4 variants of uncertain significance: the endogenous
    klc-2 gene was replaced with human KLC4, which retained most of klc-2's function, and
    five hKLC4 variants were then introduced into that background. The clinical variant
    caused early lethality with nuclear migration defects when homozygous and a weak defect
    when heterozygous.

    Important scope limit: the "clinical variant" here is the *heterozygous, late-onset*
    frameshift at residue 369 from an Undiagnosed Diseases Network proband, not the
    homozygous exon-6 deletion of the family this entry curates. The model is included
    because both truncations are predicted to remove the same cargo-binding domain, so it
    speaks to whether losing that domain is deleterious - not to this disease's allele.
  genes:
  - preferred_term: KLC4
    term:
      id: hgnc:21624
      label: KLC4
  modeled_mechanisms:
  - target: Loss of the KLC4 Cargo-Binding TPR Domain
    relationship: PERTURBS
    fidelity: LOW
    description: >-
      The only experimental test of what a truncating KLC4 allele does in a living animal
      expressing human KLC4. A homozygous truncation is lethal in this background with
      severe nuclear migration defects, which is direct evidence that the truncation is not
      tolerated - the question this node otherwise answers only by structural prediction.
    limitations: >-
      The allele is the wrong one: a residue-369 frameshift from a heterozygous late-onset
      patient, not the residue-277 truncation of this recessive childhood disease. The
      readout is also the wrong one: nuclear migration is a klc-2 function in the worm with
      no established counterpart in this disease's phenotype. And the paper notes that a
      dominant-negative effect of the truncated protein could not be reproduced in this
      system at all, because the transcript is likely subject to nonsense-mediated decay.
      Fidelity is LOW; this establishes that the domain matters, and nothing about the
      disease.
    readouts:
    - name: Nuclear migration in humanized hKLC4 worms carrying the clinical variant
      target: Loss of the KLC4 Cargo-Binding TPR Domain
      direction: ALTERED
      interpretation: >-
        Homozygous clinical variant animals show significant nuclear migration defects and
        early lethality; heterozygotes show a weak defect.
      evidence:
      - reference: PMID:37565267
        reference_title: "A humanized Caenorhabditis elegans model of hereditary spastic paraplegia-associated variants in KLC4."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "The clinical variant led to early lethality, with significant defects in nuclear migration when homozygous and a weak nuclear migration defect when heterozygous, possibly correlating with the clinical finding of late-onset HSP when the proband was heterozygous."
        explanation: The measurement behind this readout, with the authors' own hedge on its clinical correlation.
    evidence:
    - reference: PMID:37565267
      reference_title: "A humanized Caenorhabditis elegans model of hereditary spastic paraplegia-associated variants in KLC4."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "We created a humanized Caenorhabditis elegans model in which klc-2 was replaced by human KLC4 (referred to as hKLC4) and assessed the extent to which hKLC4 retained function in the worm."
      explanation: >-
        What makes this line informative for a node about human KLC4 domain loss: it is human
        KLC4 protein being tested, not a worm orthologue.
discussions:
- discussion_id: klc4_disease_name_outruns_its_published_phenotype
  kind: KNOWLEDGE_GAP
  prompt: >-
    MONDO and OMIM name this disease after retinitis pigmentosa, sensorineural hearing loss
    and demyelinating peripheral neuropathy. The abstract of its only clinical publication
    names none of the three. Where did they come from, and what should a curator do about it?
  attaches_to:
  - disease#KLC4-Related Early-Childhood-Onset Neurodegeneration
  - phenotypes#Visual Impairment
  - phenotypes#Hearing Impairment
  rationale: >-
    MedGen's definition of this concept attributes the full description - progressive walking
    difficulty, retinitis pigmentosa with blindness, sensorineural hearing loss, demyelinating
    peripheral neuropathy, severely impaired intellectual development - to Bayrakli et al.
    2015. That is the same publication this entry cites. So the features are almost certainly
    in the paper's full text, in a clinical table or case descriptions that its abstract
    compresses into the four words "progressive complicated spastic paraplegia".

    The paper is behind a paywall and its full text cannot be retrieved into the reference
    cache, and a dismech evidence snippet must be an exact substring of a cached source. So
    the entry cannot curate retinitis pigmentosa, sensorineural hearing loss or demyelinating
    neuropathy, even though the disease is named after them and they are very likely true.

    What it can do is curate one level up. A later zebrafish paper summarises the human
    phenotype as defects in vision, hearing, movement and cognition, and that sentence is
    quotable. The three phenotype records here are bound accordingly - HP:0000505 rather than
    a retinal dystrophy term, HP:0000365 rather than a sensorineural one - and each says in
    its description why.

    This is a resolvable gap, not a permanent one, and the resolution is mechanical: obtain
    the 2015 full text, cache it, and split the visual, auditory and peripheral nerve records
    to the specificity it supports. Until then, a reader should treat the disease's own name
    as the best available hypothesis about its phenotype rather than as something this entry
    has verified.

    One lead for whoever does that work. The falcon deep-research report committed alongside
    this entry had retrieval access to the 2015 paper's full text and reports retinitis
    pigmentosa progressing to blindness in the oldest patient, described in 3 of 3 affected
    siblings, alongside sensorineural hearing loss and demyelinating polyneuropathy. That is
    a provider report, not a source this entry can quote, and it is recorded here as a lead
    rather than as evidence - but it is consistent with MedGen's attribution and says the
    full text is worth obtaining.
  evidence:
  - reference: PMID:26423925
    reference_title: "Hereditary spastic paraplegia with recessive trait caused by mutation in KLC4 gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Three patients from the same family shared common features of progressive complicated spastic paraplegia."
    explanation: >-
      The whole of the abstract's clinical description. The gap is the distance between this
      sentence and the disease's four-feature name.
  - reference: PMID:36222498
    reference_title: "KLC4 shapes axon arbors during development and mediates adult behavior."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Multiple neural systems are affected in the human disease caused by KLC4 mutation; patients show defects in vision, hearing, movement and cognition (Bayrakli et al., 2015)."
    explanation: >-
      The intermediate level of description that is quotable, and the reason this entry
      curates four organ systems rather than either one phenotype or four named diagnoses.
- discussion_id: klc4_two_alleles_two_inheritance_modes
  kind: KNOWLEDGE_GAP
  prompt: >-
    KLC4 has two published patients: three siblings homozygous for a residue-277 truncation
    with early-childhood multisystem disease, and one man heterozygous for a residue-369
    truncation with myelopathy and neuropathy from age fifty. One gene, two truncations
    predicted to do the same thing, two inheritance modes, and fifty years between the
    onsets. Are these one disease or two?
  attaches_to:
  - pathophysiology#Loss of the KLC4 Cargo-Binding TPR Domain
  - genetic#KLC4
  - animal_models#Humanized hKLC4 Caenorhabditis elegans
  rationale: >-
    This entry curates them as two, and the reason is dosage. The recessive family's
    unaffected heterozygous parents and siblings are the control the dominant case lacks: if
    one truncated KLC4 allele were sufficient to cause disease, four heterozygous relatives
    should not have been well. So either the residue-369 allele does something the
    residue-277 allele does not - a dominant-negative effect on the kinesin complex rather
    than simple loss - or something else contributes in that proband.

    Both possibilities are live in the literature and neither is settled. The 2023 paper
    raises the dominant-negative reading itself and says it could not be tested in the worm,
    because the truncated transcript is likely destroyed by nonsense-mediated decay. It also
    reports that other variants were found by genome sequencing in the same individual and
    that their contribution is under investigation - and notes his celiac disease and
    occupational herbicide and pesticide exposure, both of which can produce myelopathy and
    neuropathy.

    The practical consequence for this entry is a boundary rather than a mystery: the
    late-onset case is not curated as a phenotype, prevalence entry or subtype of this
    disease, and the C. elegans model is linked only to the molecular domain-loss node with
    fidelity LOW, because the allele it tests is that patient's rather than this family's.

    What would resolve it is a second recessive family, or a functional comparison of the two
    truncated proteins in the same system with wild-type protein co-expressed - the
    experiment that separates loss of function from dominant negative, and the one the worm
    model explicitly could not perform.
  evidence:
  - reference: PMID:37565267
    reference_title: "A humanized Caenorhabditis elegans model of hereditary spastic paraplegia-associated variants in KLC4."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We identified an individual with late-onset HSP with a heterozygous variant in KLC4 predicted to cause a frame shift at residue 369, closely followed by a premature stop codon."
    explanation: The second patient, whose allele and inheritance mode differ from this disease's.
  - reference: PMID:37565267
    reference_title: "A humanized Caenorhabditis elegans model of hereditary spastic paraplegia-associated variants in KLC4."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A male individual with the clinical KLC4 variant presented to the Undiagnosed Diseases Network (UDN) with slowly progressive myelopathy and neuropathy"
    explanation: >-
      His presentation, which is separated from this disease's by roughly fifty years of
      onset and by the absence of visual, auditory and cognitive involvement.
  - reference: PMID:37565267
    reference_title: "A humanized Caenorhabditis elegans model of hereditary spastic paraplegia-associated variants in KLC4."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The truncated KLC4 protein variant could conceivably be acting in a dominant-negative manner in the proband, which would not be recapitulated in C. elegans owing to likely nonsense-mediated decay of the transcript."
    explanation: >-
      The mechanism that would reconcile the two inheritance modes, together with the reason
      it remains untested. Graded OTHER because the sentence is the authors' interpretive
      discussion rather than a result from either their human or their worm arm.
  - reference: PMID:26423925
    reference_title: "Hereditary spastic paraplegia with recessive trait caused by mutation in KLC4 gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Meanwhile, the unaffected parents and two siblings were heterozygous and one sibling was homozygous wild type."
    explanation: >-
      The control that makes the two cases hard to reconcile: four heterozygous carriers of a
      truncating KLC4 allele, none of them affected.
- discussion_id: klc4_zebrafish_patterning_versus_human_neurodegeneration
  kind: HUMAN_MODEL_MISMATCH
  prompt: >-
    The klc4 mutant zebrafish is adult viable with no early neurodegeneration, and its defect
    is one of axon patterning rather than axon survival. The human disease is called a
    neurodegeneration. Which is right about KLC4?
  attaches_to:
  - animal_models#klc4 mutant zebrafish
  - pathophysiology#Disordered Patterning Across Multiple Neural Systems
  - phenotypes#Progressive Complicated Spastic Paraplegia
  rationale: >-
    The fish authors are explicit that their mutant's neurons look healthy, that axons grow
    faster rather than slower, and that there is no sign of early degeneration - and they read
    the human disease accordingly, as possibly caused by defects in developmental patterning
    rather than by degeneration. The human report describes a progressive disorder, and the
    disease's name in MONDO and OMIM begins with the word neurodegeneration.

    These need not be contradictory. A developmental patterning defect can present as
    progressive loss of function if a mispatterned circuit decompensates with age or fails to
    keep pace with growth, and "progressive" in the clinical report is a description of
    course, not of pathology. No neuropathology from an affected person has been published,
    so no one has looked at whether neurons are actually dying.

    But they are different mechanistic claims with different consequences, and the entry does
    not choose between them. The pathograph is built on the patterning account, because that
    is where the measurements are, and the fish's viability is curated as a
    FAILS_TO_RECAPITULATE link against the spastic paraplegia phenotype rather than omitted.

    Two caveats belong with the mismatch. Fish have no corticospinal tract, so the absence of
    spastic paraplegia in the model is partly a fact about its anatomy. And vertebrates carry
    four kinesin light chains with overlapping neuronal expression, so paralogue redundancy
    may differ between species - the fish may simply be better compensated than a child.
  evidence:
  - reference: PMID:36222498
    reference_title: "KLC4 shapes axon arbors during development and mediates adult behavior."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Klc4 mutant neurons do not have a general growth defect, in that their axons grow faster than wild type axons. In addition, klc4 mutants are adult viable and show no signs of early neurodegeneration."
    explanation: The negative result at the centre of the mismatch.
  - reference: PMID:36222498
    reference_title: "KLC4 shapes axon arbors during development and mediates adult behavior."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Our results also give insight into mechanisms of the human disease caused by KLC4 mutation, which may be caused by defects in developmental patterning."
    explanation: >-
      The alternative reading of the human disease that the model supports, hedged by its own
      authors.
  - reference: PMID:26423925
    reference_title: "Hereditary spastic paraplegia with recessive trait caused by mutation in KLC4 gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Three patients from the same family shared common features of progressive complicated spastic paraplegia."
    explanation: >-
      The word "progressive" is the whole of the published evidence that this disease is
      degenerative, and it describes a clinical course rather than a pathology.
📚

References & Deep Research

References

3
PMID:26423925
Hereditary spastic paraplegia with recessive trait caused by mutation in KLC4 gene.
No top-level findings curated for this source.
PMID:36222498
KLC4 shapes axon arbors during development and mediates adult behavior.
No top-level findings curated for this source.
PMID:37565267
A humanized Caenorhabditis elegans model of hereditary spastic paraplegia-associated variants in KLC4.
No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Falcon ▸
Disease Characteristics Research Template
Edison Scientific Literature 11 citations 2026-09-04T15:52:22.760001

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

  • Disease Name: KLC4-Related Early-Childhood-Onset Neurodegeneration
  • MONDO ID: (if available)
  • Category: Mendelian

Research Objectives

Please provide a comprehensive research report on KLC4-Related Early-Childhood-Onset Neurodegeneration covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

  • What is the disease? Provide a concise overview.
  • What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
  • What are the common synonyms and alternative names?
  • Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

  • Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
  • Risk Factors:

    Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

  • Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  • Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
  • Protective Factors:

    Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

  • Genetic protective factors (protective variants, modifier alleles)
  • Environmental protective factors (diet, lifestyle, exposures that reduce risk)
  • Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

    Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

  • Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

    Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

  • Pathogenic Variants:
  • Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  • Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  • Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  • Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  • Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
  • Functional consequences (loss of function, gain of function, dominant negative)
  • Modifier Genes: Genes that modify disease severity or expression
  • Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

    Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

  • Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

    Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

  • Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

    Search first: CDC databases, WHO, PubMed, NHANES

  • Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

    Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

Present this section as an ordered causal chain first, then the detail below. Open with a numbered sequence of mechanistic steps running from the initiating lesion (mutation, exposure, infection) to the clinical manifestation, one step per line, each naming what it causes next. State the causal verb explicitly ("leads to", "results in") and say where a step is inferred rather than demonstrated. Where the mechanism branches, show the branch. The categories below are a checklist of what to cover within those steps, not the organizing structure — a step may draw on several of them, and a category may contribute to several steps.

  • Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

    Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

  • Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

    Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

  • Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

    Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

  • Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

    Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

  • Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

    Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

  • Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

    Search first: PubMed, Gene Ontology, Reactome

  • Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

    Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

  • Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

    Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

  • Molecular Profiling (if available):
  • Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  • Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  • Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
  • Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  • Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
  • Advanced Technologies (if applicable):
  • Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  • Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
  • Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  • Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

  • Organ Level:
  • Primary organs directly affected
  • Secondary organ involvement (complications, secondary effects)
  • Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

    Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

  • Tissue and Cell Level:
  • Specific tissue types affected (epithelial, connective, muscle, nervous)
  • Specific cell populations targeted (with Cell Ontology terms)

    Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

  • Subcellular Level:
  • Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

    Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

  • Localization:
  • Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
  • Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

  • Onset:
  • Typical age of onset (congenital, pediatric, adult, geriatric)
  • Onset pattern (acute, subacute, chronic, insidious)

    Search first: OMIM, Orphanet, HPO, PubMed

  • Progression:
  • Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
  • Progression rate (rapid, slow, variable)
  • Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  • Disease duration (self-limited, chronic lifelong)

    Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

  • Patterns:
  • Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
  • Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

  • Epidemiology:
  • Prevalence (cases per 100,000 at given time)
  • Incidence (new cases per 100,000 per year)

    Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

  • For Genetic Etiology:
  • Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  • Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
  • Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
  • Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
  • Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
  • Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
  • Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
  • Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
  • Population Demographics:
  • Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  • Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  • Geographic distribution of specific variants
  • Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
  • Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

  • Clinical Tests:
  • Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
  • Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  • Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
  • Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
  • Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
  • Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
  • Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
  • Genetic Testing:

    Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

  • Overview of recommended genetic testing approach
  • Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
  • Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
  • Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
  • Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
  • Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
  • Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
  • FISH > Search first: ClinVar, cytogenetics databases, PubMed
  • Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
  • Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
  • Omics-Based Diagnostics (if applicable):
  • RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
  • Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
  • Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
  • Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
  • Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
  • Clinical Criteria:
  • Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
  • Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
  • Screening:
  • Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

  • Survival and Mortality:
  • Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
  • Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
  • Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
  • Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
  • Morbidity and Function:
  • Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
  • Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
  • Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
  • Disease Course:
  • Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
  • Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
  • Prediction:
  • Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
  • Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

  • Pharmacotherapy:
  • Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  • Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
  • Advanced Therapeutics:
  • Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  • Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
  • RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
  • Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  • Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
  • Surgical and Interventional:
  • Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
  • Supportive and Rehabilitative:
  • Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
  • Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
  • Experimental:
  • Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
  • Treatment Outcomes:
  • Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
  • Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
  • Treatment Strategy:
  • Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
  • Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
  • Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

13. Prevention

  • Prevention Levels:
  • Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
  • Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
  • Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
  • Immunization: Vaccine strategies (if applicable)

    Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

  • Screening and Early Detection:
  • Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
  • Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
  • Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
  • Behavioral Interventions: Lifestyle modifications to reduce risk

    Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

  • Counseling: Genetic counseling (risk assessment, family planning guidance)

    Search first: NSGC resources, ACMG guidelines, GeneReviews

  • Public Health:
  • Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
  • Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
  • Prophylaxis: Preventive medications or procedures

    Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

  • Taxonomy: Species affected (with NCBI Taxon identifiers)

    Search first: NCBI Taxonomy

  • Breed: Specific breeds affected (with VBO identifiers if applicable)

    Search first: VBO (Vertebrate Breed Ontology)

  • Gene: Orthologous genes in other species (with NCBI Gene IDs)

    Search first: NCBI Gene

  • Natural Disease:
  • Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  • Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
  • Comparative Biology:
  • Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
  • Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
  • Transmission (if applicable):
  • Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
  • Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

  • Model Types:
  • Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
  • Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  • Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
  • Genetic Models:
  • Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
  • Model Characteristics:
  • Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
  • Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
  • Applications:
  • Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
  • Resources:
  • Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

  • Cite primary literature (PMID preferred) for all mechanistic and clinical claims
  • Prioritize recent reviews and landmark papers
  • Include direct quotes from abstracts where possible to support key statements
  • Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (NCIT terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

KLC4-Related Early-Childhood-Onset Neurodegeneration

Executive summary and evidence status

KLC4-related early-childhood-onset neurodegeneration is a descriptive label for an extremely rare, progressive, autosomal-recessive complicated hereditary spastic paraplegia (HSP) associated with biallelic loss of KLC4, encoding kinesin light chain 4. The established human evidence consists of three affected siblings from one consanguineous family reported by Bayrakli et al. in 2015. No independent human replication cohort, disease-specific natural-history study, diagnostic criteria, therapy, or clinical trial was identified. Accordingly, the gene–disease relationship is biologically plausible and supported by segregation plus model-organism data, but estimates of phenotype frequency, penetrance, prognosis, and epidemiology remain highly uncertain. (bayrakli2015hereditaryspasticparaplegia pages 1-2, haynes2022klc4shapesaxon pages 2-3, burnett2024therolesofa pages 107-118)

Defining publication: Bayrakli F, et al. Hereditary spastic paraplegia with recessive trait caused by mutation in KLC4 gene. Journal of Human Genetics. Published online 1 October 2015;60:763–768. PMID: 26423925. DOI/URL: https://doi.org/10.1038/jhg.2015.109. (bayrakli2015hereditaryspasticparaplegia pages 1-2, burnett2024therolesofa pages 107-118)

The compact evidence appraisal below highlights the distinction between direct human observations and mechanistic inference.

Domain Best-supported finding Evidence type/strength Key limitation
Defining cohort Three affected children were reported in one consanguineous family from eastern Turkey. (bayrakli2015hereditaryspasticparaplegia pages 1-2, bayrakli2015hereditaryspasticparaplegia pages 2-3) Human family study; foundational but single-family evidence No independent human replication cohort was identified.
Onset and course Early development and walking were initially normal; deterioration of gait, vision, and hearing began at approximately 3 years and progressed. One individual lost walking by age 12. (bayrakli2015hereditaryspasticparaplegia pages 3-4, bayrakli2015hereditaryspasticparaplegia pages 2-3) Direct longitudinal clinical histories from three affected relatives Retrospective histories; no standardized natural-history assessments.
Core phenotype Progressive complicated hereditary spastic paraplegia with lower-limb-predominant pyramidal dysfunction, weakness, gait loss, cognitive impairment, retinitis pigmentosa or blindness, sensorineural hearing loss or deafness, and demyelinating polyneuropathy. (bayrakli2015hereditaryspasticparaplegia pages 3-4, bayrakli2015hereditaryspasticparaplegia pages 2-3) Direct human clinical, ophthalmologic, audiologic, and electrophysiologic observations Frequencies derived from three related patients cannot establish the full phenotypic spectrum.
Neuroimaging and laboratory findings MRI abnormalities involved dentate nuclei, corticospinal pathways or internal capsules, and subcortical or periventricular white matter, with mild cerebral or cerebellar atrophy and a thin corpus callosum; spinal MRI was normal. Broad metabolic testing was largely unrevealing, although blood lactate was elevated in some descriptions. (bayrakli2015hereditaryspasticparaplegia pages 3-4, bayrakli2015hereditaryspasticparaplegia pages 2-3) Direct clinical imaging and biochemical evidence Findings are neither validated biomarkers nor known to be specific to KLC4 disease.
Causal variant A homozygous KLC4 c.853_871del19 deletion in exon 6 creates a premature termination codon at amino acid 277 and is predicted to remove most cargo-binding tetratricopeptide repeats and the entire C-terminal region. (bayrakli2015hereditaryspasticparaplegia pages 4-6) WES, Sanger confirmation, cDNA sequencing, conservation, and predicted protein consequence Transcript accession and standardized HGVS protein notation were not supplied in the retrieved evidence; direct human-cell functional testing was limited.
Inheritance and segregation All three affected individuals were homozygous; the unaffected parents and two siblings were heterozygous, and another unaffected sibling was homozygous wild type, supporting autosomal-recessive inheritance. (bayrakli2015hereditaryspasticparaplegia pages 1-2) Strong within-family cosegregation Penetrance, expressivity, germline-mosaicism risk, and genotype–phenotype relationships cannot be estimated from one pedigree.
Population evidence The deletion was absent from 650 in-house exomes and legacy public controls, including the 1000 Genomes Project and Exome Variant Server. (bayrakli2015hereditaryspasticparaplegia pages 4-6) Supportive rarity evidence available in 2015 A current ancestry-matched gnomAD frequency was not established in the retrieved sources; carrier frequency is unknown.
Zebrafish mechanism klc4-mutant zebrafish showed impaired stabilization of nascent sensory-axon branches, altered microtubule dynamics, reduced acetylated tubulin, defective Rab5-positive endosomal transport, abnormal peripheral-axon fasciculation, touch hypersensitivity, and adult anxiety-like behavior. (haynes2022klc4shapesaxon pages 2-3, haynes2022klc4shapesaxon pages 12-14, haynes2022klc4shapesaxon pages 17-18, haynes2022klc4shapesaxon pages 10-12) Peer-reviewed in-vivo model using live imaging and behavioral assays; strong evidence for conserved neuronal functions The model did not show early degeneration or directly test the human deletion; behavioral findings must not be treated as human phenotypes.
Cellular mechanism KLC4 participates in a CLN6–CRMP2–KLC4 complex associated with anterograde ER-derived-vesicle trafficking in cortical neurites; pathway perturbation correlates with impaired neurite growth and arborization. (koh2021acln6crmp2klc4complex pages 5-7, koh2021acln6crmp2klc4complex pages 1-5) Biochemical and primary mouse-neuron evidence; mechanistically supportive Experiments primarily manipulated CLN6 rather than KLC4, making direct applicability to KLC4-associated disease inferential.
Diagnostics Molecular confirmation can use exome or genome sequencing or an appropriate neurodegeneration or HSP panel, followed by variant confirmation, segregation analysis, and careful interpretation. MRI, audiology, ophthalmology, nerve-conduction studies, and metabolic testing characterize disease and exclude mimics. (bayrakli2015hereditaryspasticparaplegia pages 2-3, bayrakli2015hereditaryspasticparaplegia pages 1-2) Approach supported by the defining family’s diagnostic workflow No validated KLC4-specific diagnostic criteria, biochemical assay, or biomarker exists.
Treatment and trials No KLC4-specific disease-modifying therapy or relevant clinical trial was identified; management is necessarily supportive and phenotype-directed. Negative targeted trial search and absence of treatment evidence in the defining report No response rates, adverse-event data, treatment algorithm, or evidence that experimental CRMP2 modulation benefits KLC4 disease.
Epidemiology Only three related affected individuals constitute the established human evidence base; prevalence, incidence, carrier frequency, geographic distribution, and sex ratio are unknown. (bayrakli2015hereditaryspasticparaplegia pages 1-2, burnett2024therolesofa pages 107-118) Ultra-rare single-family ascertainment The case count is too small for population estimates or robust phenotype frequencies.
Terminology and identifiers The primary publication names the condition recessive KLC4-associated hereditary spastic paraplegia; “KLC4-related early-childhood-onset neurodegeneration” is a descriptive knowledge-base label rather than a verified standardized disease name. (haynes2022klc4shapesaxon pages 2-3, burnett2024therolesofa pages 107-118) Terminology grounded in the primary report and later mechanistic literature No disease-specific MONDO, OMIM phenotype, Orphanet, MeSH, or dedicated ICD identifier was verified; identifiers must not be inferred from the gene association alone.

Table: Compact appraisal of the human, genetic, mechanistic, diagnostic, and epidemiologic evidence for KLC4-related early-childhood-onset neurodegeneration. It emphasizes that the disease definition rests on one three-patient family and separates direct observations from model-based inference.

1. Disease information

Definition

The disorder is an early-childhood-onset, chronically progressive neurodegenerative/axonopathic syndrome dominated by lower-extremity pyramidal dysfunction, with additional peripheral neuropathy, visual and auditory degeneration, cognitive impairment, and brain white-matter abnormalities. The primary authors called it “hereditary spastic paraplegia with recessive trait caused by mutation in KLC4 gene.” “KLC4-related neurodegeneration,” “KLC4-associated complicated HSP,” and “autosomal-recessive KLC4-related spastic paraplegia” are reasonable descriptive synonyms, but are not necessarily standardized ontology labels. (bayrakli2015hereditaryspasticparaplegia pages 3-4, bayrakli2015hereditaryspasticparaplegia pages 2-3)

Identifiers

  • Gene: KLC4 (kinesin light chain 4).
  • PMID: 26423925 for the defining clinical report. (burnett2024therolesofa pages 107-118)
  • MONDO: no disease-specific MONDO identifier was verified.
  • OMIM/Orphanet: no dedicated phenotype identifier was verified from the retrieved evidence.
  • ICD-10/ICD-11: no KLC4-specific code; clinically it falls under hereditary spastic paraplegia/hereditary ataxia groupings.
  • MeSH: no KLC4-specific disease heading; broader headings include Spastic Paraplegia, Hereditary and Neurodegenerative Diseases.

These should remain unmapped rather than inferred until confirmed against current ontology releases.

Source granularity

Evidence is individual-patient/family-level research data, subsequently summarized at disease level. It is not an EHR-derived population cohort or registry. All apparent human frequencies are therefore counts among three related patients, not population estimates. (bayrakli2015hereditaryspasticparaplegia pages 1-2, bayrakli2015hereditaryspasticparaplegia pages 2-3)

2. Etiology, risk, protection, and environment

Causal factor

The reported cause is a germline homozygous 19-bp deletion, KLC4 c.853_871del19, in exon 6. It creates a premature termination codon at amino acid 277 and is predicted to truncate approximately half the protein, including most tetratricopeptide-repeat cargo-binding domains and the entire C-terminal region. RNA cDNA PCR/sequencing confirmed expression of the deletion-containing transcript, but the human report did not provide a direct neuronal transport assay or quantitative protein study. (bayrakli2015hereditaryspasticparaplegia pages 4-6)

Genetic risk factors

  • Biallelic pathogenic loss-of-function alleles: established candidate causal architecture.
  • Consanguinity/family history: increases the probability that both parents carry the same rare allele; the defining pedigree was consanguineous. (bayrakli2015hereditaryspasticparaplegia pages 2-3)
  • No susceptibility loci, modifier genes, common-risk alleles, or genotype–phenotype correlations have been established.

Environmental and protective factors

No toxin, infection, radiation, diet, smoking, exercise, occupational exposure, sex, or other environmental factor has been shown to cause, modify, or protect against this Mendelian disorder. No protective KLC4 allele or modifier has been reported. Appropriate nutrition, mobility, vaccination, and rehabilitation may reduce secondary morbidity but do not prevent the genetic disease.

Gene–environment interaction

No KLC4-specific interaction is known. Environmental stressors could plausibly affect function in already vulnerable long axons, but this is a general axon-biology hypothesis, not demonstrated KLC4 disease evidence.

3. Phenotypes

The reported children developed normally enough to walk independently at approximately 12–13 months, followed by deterioration beginning near 3 years. The course was progressive; one patient lost walking by age 12 and, by age 19, had become blind and deaf. (bayrakli2015hereditaryspasticparaplegia pages 3-4, bayrakli2015hereditaryspasticparaplegia pages 2-3)

Phenotype Type and characteristics Observed frequency Suggested HPO annotation
Progressive spastic paraplegia Sign; childhood onset, lower-limb predominant, progressive and severe 3/3 reported family cases Spastic paraplegia HP:0001258; progressive spasticity HP:0002191
Gait deterioration/loss of ambulation Functional manifestation; onset around 3 years; one lost walking at 12 3/3 Abnormal gait HP:0001288; inability to walk HP:0002540
Hyperreflexia, Babinski, clonus Pyramidal signs; lower limbs prominent Reported in younger patients; oldest later had absent reflexes with neuropathy Hyperreflexia HP:0001347; Babinski sign HP:0003487; ankle clonus HP:0011448
Weakness and muscle atrophy Sign; lower limbs worse than upper limbs; progressive Reported across cases Muscle weakness HP:0001324; muscular atrophy HP:0003202
Demyelinating polyneuropathy Electrophysiologic abnormality; lower limbs more severe 3/3 described Demyelinating peripheral neuropathy HP:0007108
Sensorineural hearing loss/deafness Sign; progressive, severe or near-total 3/3 Sensorineural hearing impairment HP:0000407
Retinitis pigmentosa/visual loss Ophthalmic sign; progressive to blindness in oldest patient 3/3 described Retinitis pigmentosa HP:0000510; visual impairment HP:0000505
Cognitive impairment Neurobehavioral manifestation; severe in at least the oldest patient (reported IQ 25–30) 3/3 described qualitatively Intellectual disability HP:0001249
Ataxic gait Sign; reported particularly in a younger patient At least 1/3 Gait ataxia HP:0002066
Nystagmus/pale optic discs Ophthalmic signs Reported in individual patients Nystagmus HP:0000639; optic pallor HP:0000543
White-matter/internal-capsule and dentate abnormalities MRI sign; bilateral, with mild cerebral/cerebellar atrophy and thin corpus callosum reported Multiple patients Cerebral white-matter abnormality HP:0002500; thin corpus callosum HP:0002079; cerebral atrophy HP:0002059; cerebellar atrophy HP:0001272
Elevated blood lactate Laboratory abnormality; not consistent enough to constitute a biomarker Some descriptions/patients Lactic acidosis/elevated lactate HP:0003128, applied cautiously

The denominator is only three related individuals; “3/3” must not be interpreted as a robust 100% disease frequency. Quality-of-life instruments were not administered, but loss of walking, hand skills, hearing, vision, and cognition implies profound effects on communication, education, independence, mobility, and caregiver burden. (bayrakli2015hereditaryspasticparaplegia pages 2-3, bayrakli2015hereditaryspasticparaplegia pages 3-4)

4. Genetic and molecular information

Gene and protein

KLC4 encodes a light-chain component of kinesin-1. Kinesin heavy chains provide ATPase/microtubule motor activity; light chains participate in cargo recognition and motor regulation. KLC architecture includes a heavy-chain-binding heptad-repeat region, six tetratricopeptide repeats, a C-terminal lipid-binding amphipathic helix, and an autoinhibitory motif. (haynes2022klc4shapesaxon pages 2-3)

Reported pathogenic variant

  • Variant: c.853_871del19, exon 6; homozygous and germline.
  • Class: frameshifting deletion/premature stop; exact standardized protein HGVS and reference transcript were not supplied in the retrieved text.
  • Consequence: predicted severe loss of cargo-binding/C-terminal function; nonsense-mediated decay versus stable truncated protein was not resolved.
  • Segregation: all three affected relatives were homozygous; parents and two unaffected siblings were heterozygous; one unaffected sibling was homozygous reference. (bayrakli2015hereditaryspasticparaplegia pages 1-2)
  • Population data: absent from 650 in-house exomes and the then-used 1000 Genomes, dbSNP, and Exome Variant Server controls. A current ancestry-matched gnomAD allele count was not established here. (bayrakli2015hereditaryspasticparaplegia pages 4-6)
  • Classification: the report treated the allele as causal. A contemporary laboratory should independently apply ACMG/AMP criteria using the correct transcript, segregation, rarity, predicted loss-of-function relevance, and current ClinVar/gnomAD evidence rather than copying a historical classification.

No pathogenic missense series, structural variant, somatic variant, modifier gene, epigenetic signature, chromosomal abnormality, anticipation, or founder haplotype has been established.

5. Environmental information

No environmental, lifestyle, infectious, or toxic contributor is established. The condition is not contagious or zoonotic. Elevated lactate in some patients does not demonstrate a toxin, dietary cause, or primary mitochondrial disorder; broad metabolic, amino-acid, organic-acid, lysosomal-enzyme, and very-long-chain-fatty-acid testing was largely normal. (bayrakli2015hereditaryspasticparaplegia pages 2-3, bayrakli2015hereditaryspasticparaplegia pages 3-4)

6. Mechanism and pathophysiology

Ordered causal chain

  1. Biallelic KLC4 c.853_871del19 leads to a premature stop at approximately residue 277 and predicted loss of most cargo-binding tetratricopeptide repeats plus the C-terminal domain. Human genetic evidence; protein consequence predicted. (bayrakli2015hereditaryspasticparaplegia pages 4-6)
  2. Loss of functional KLC4 is inferred to lead to defective cargo selection/regulation by kinesin-1 in neurons. The exact human disease cargo is unknown.
  3. Defective KLC4 function leads to altered Rab5-positive endosomal transport, reduced microtubule stabilization/acetylated tubulin, and abnormal branch stabilization in zebrafish sensory axons. Demonstrated in vivo in zebrafish, not demonstrated in patient neurons. (haynes2022klc4shapesaxon pages 2-3, haynes2022klc4shapesaxon pages 12-14, haynes2022klc4shapesaxon pages 17-18)
  4. These transport and cytoskeletal abnormalities lead to disordered axonal branching, tiling, polarity, and inappropriate fasciculation, compromising circuit formation. Demonstrated in zebrafish. (haynes2022klc4shapesaxon pages 1-2, haynes2022klc4shapesaxon pages 10-12)
  5. Branch A—developmental: abnormal axon morphogenesis is inferred to lead to early motor/circuit dysfunction.
  6. Branch B—maintenance: chronically inadequate long-distance cargo delivery is inferred to lead to distal axonal vulnerability and degeneration, producing corticospinal and peripheral-nerve dysfunction.
  7. Progressive central and peripheral axon dysfunction results in spastic paraplegia, weakness, gait loss, and demyelinating polyneuropathy; involvement of visual, auditory, and cognitive pathways results in retinopathy/blindness, sensorineural deafness, and intellectual impairment. Clinical manifestations demonstrated; connecting molecular steps remain inferred. (bayrakli2015hereditaryspasticparaplegia pages 3-4, bayrakli2015hereditaryspasticparaplegia pages 2-3)

Supporting mechanistic evidence

In peer-reviewed zebrafish work, KLC4 was expressed in developing brain regions, trigeminal and lateral-line ganglia, and Rohon–Beard sensory neurons. Mutants had a lower proportion of anterogradely moving Rab5 vesicles and shorter maximum anterograde runs, although vesicle velocity was unchanged. Microtubule plus ends polymerized faster, run duration was reduced, and acetylated-tubulin labeling in nascent branches was diminished. No early axonal degeneration was observed, indicating that this model primarily demonstrated developmental morphogenesis rather than the complete human neurodegenerative course. (haynes2022klc4shapesaxon pages 2-3, haynes2022klc4shapesaxon pages 12-14, haynes2022klc4shapesaxon pages 17-18)

A separate experimental pathway identifies KLC4 in a CLN6–CRMP2–KLC4 complex associated with ER-derived vesicles in cortical neurites. Co-immunoprecipitation and neuronal localization support interaction, but most functional perturbations involved CLN6 rather than KLC4; applicability to KLC4 disease is therefore supportive but indirect. (koh2021acln6crmp2klc4complex pages 5-7, koh2021acln6crmp2klc4complex pages 1-5)

Ontology suggestions

  • GO biological process: microtubule-based movement; anterograde axonal transport; endosomal transport; axonogenesis; axon extension; axon guidance; regulation of microtubule polymerization; neuron projection morphogenesis; organelle transport along microtubules.
  • GO cellular component: kinesin complex; microtubule cytoskeleton; axon; neuronal cell body; endosome; ER-derived transport vesicle.
  • Cell Ontology: neuron CL:0000540; sensory neuron CL:0000101; cortical neuron; retinal photoreceptor cell; auditory sensory cell; upper motor neuron and peripheral neuron as clinically implicated but not directly profiled.

No disease-specific transcriptomic, proteomic, metabolomic, lipidomic, single-cell, spatial-transcriptomic, patient-iPSC, organoid, or CRISPR-screen profile was identified.

7. Anatomical structures affected

  • Primary system: central and peripheral nervous systems.
  • Brain: corticospinal/internal-capsule pathways, subcortical and periventricular white matter, cerebellar dentate nuclei, corpus callosum, cerebrum, and cerebellum. Findings were bilateral; no consistent lateralization was reported. (bayrakli2015hereditaryspasticparaplegia pages 3-4, bayrakli2015hereditaryspasticparaplegia pages 2-3)
  • Peripheral nerves: electrophysiologic demyelinating polyneuropathy, lower limbs more severely affected.
  • Eye: retina/optic pathway, with retinitis pigmentosa, optic pallor, and blindness.
  • Auditory system: sensorineural hearing pathway.
  • Spinal cord: clinically implicated corticospinal tracts, although structural spinal MRI was normal. (bayrakli2015hereditaryspasticparaplegia pages 2-3, bayrakli2015hereditaryspasticparaplegia pages 3-4)

Suggested UBERON concepts include nervous system UBERON:0001016, brain UBERON:0000955, spinal cord UBERON:0002240, peripheral nervous system UBERON:0000010, retina UBERON:0000966, corpus callosum, cerebral white matter, and cerebellum UBERON:0002037. Subcellular annotations should emphasize kinesin complex, axonal microtubules, endosomes, and ER-derived vesicles.

8. Temporal development

  • Presymptomatic/early phase: apparently normal early development and walking at 12–13 months.
  • Initial symptomatic phase: insidious deterioration of gait, hearing, and vision around age 3.
  • Intermediate phase: increasing spasticity, weakness, atrophy, neuropathy, loss of skilled hand movements, and sensory impairment.
  • Advanced phase: loss of ambulation, blindness, deafness, and severe cognitive/functional disability in the oldest reported individual. (bayrakli2015hereditaryspasticparaplegia pages 2-3, bayrakli2015hereditaryspasticparaplegia pages 3-4)

The course is chronic, progressive, and apparently lifelong; no remission or episodic pattern was reported. Rate varied by function and patient, but the sample is insufficient to define stages formally. Early childhood is plausibly a developmental vulnerability window because KLC4 regulates axon morphogenesis in vivo; whether presymptomatic intervention would alter human disease is unknown. (haynes2022klc4shapesaxon pages 2-3)

9. Inheritance and population

  • Inheritance: autosomal recessive.
  • Penetrance: apparently complete for homozygotes within the one pedigree, but population penetrance is unknown.
  • Expressivity: some inter-individual and age-related variation was present; robust bounds cannot be estimated.
  • Consanguinity: central to ascertainment in the defining family.
  • Sex: two girls (ages 8 and 12) and one boy (age 19) were described; this cannot establish a sex ratio. (bayrakli2015hereditaryspasticparaplegia pages 2-3, bayrakli2015hereditaryspasticparaplegia pages 3-4)
  • Prevalence/incidence/carrier frequency: unknown. Only three related affected individuals constitute the established clinical evidence base.
  • Founder effect/geographic distribution: the family was from eastern Turkey, but no founder haplotype or regional enrichment was demonstrated. (bayrakli2015hereditaryspasticparaplegia pages 1-2)
  • Anticipation and germline mosaicism: not reported and not expected from the known frameshift mechanism, though parental germline mosaicism can never be categorically excluded in counseling.

For two heterozygous carrier parents, the standard Mendelian risk for each conception is 25% affected, 50% carrier, and 25% neither variant-bearing nor affected, assuming accurate variant interpretation and no complicating factors.

10. Diagnostics

Clinical evaluation

Suspect KLC4-related disease in a child with initially near-normal motor development followed by progressive complicated HSP, especially when accompanied by sensorineural deafness, retinal degeneration, cognitive impairment, demyelinating neuropathy, white-matter/internal-capsule abnormalities, and consanguinity.

Recommended characterization includes neurologic and developmental assessment; ophthalmology with fundus examination and electroretinography; formal audiology; brain and spinal MRI; nerve-conduction studies/EMG; mobility, swallowing, respiratory, nutritional, orthopedic, and communication assessments. Broad metabolic testing is useful for differential diagnosis but is not a KLC4 biomarker. (bayrakli2015hereditaryspasticparaplegia pages 2-3)

Genetic testing strategy

  1. Trio WES or WGS is the preferred discovery approach because the phenotype overlaps many complicated HSP, leukodystrophy, mitochondrial, lysosomal, retinal, and deafness syndromes.
  2. A comprehensive HSP/neurodegeneration panel may be used if it includes KLC4 with adequate exon-level and copy-number coverage.
  3. Confirm candidate variants by an orthogonal method and perform parental/sibling segregation.
  4. Review current gnomAD, ClinVar, transcript annotation, predicted loss-of-function relevance, and phenotype match under ACMG/AMP criteria.
  5. RNA studies may help resolve splice or transcript effects; the original study used cDNA sequencing. (bayrakli2015hereditaryspasticparaplegia pages 1-2)

Single-gene testing is efficient for relatives once a familial allele is known. CMA, karyotyping, FISH, mitochondrial-DNA testing, and repeat-expansion assays are not first-line for this specific lesion but may be appropriate if sequencing is negative or the phenotype suggests an alternative diagnosis. No validated KLC4 enzyme assay, protein biomarker, liquid biopsy, or methylation episignature exists.

Differential diagnosis

Important alternatives include other complicated HSPs, neuronal ceroid lipofuscinoses, mitochondrial disorders, peroxisomal/leukodystrophy syndromes, hereditary motor-sensory neuropathies, and syndromes combining spasticity with retinopathy or deafness. Distinction depends on molecular testing, metabolic/lysosomal studies, MRI pattern, electrodiagnostics, ophthalmology, and audiology. There are no standardized KLC4-specific clinical criteria or newborn-screening programs.

11. Outcome and prognosis

The three-patient family demonstrates substantial progressive morbidity: gait decline from about age 3, severe motor impairment, peripheral neuropathy, progressive vision and hearing loss, cognitive disability, and loss of ambulation by adolescence in at least one patient. (bayrakli2015hereditaryspasticparaplegia pages 3-4)

No survival rate, life expectancy, mortality rate, validated prognostic biomarker, quality-of-life score, or treated-versus-untreated outcome is available. Recovery of established neurologic loss was not reported. Age and baseline functional severity may correlate with accumulated disability, but this is descriptive rather than a validated prognostic model.

Likely secondary complications requiring surveillance include contractures, deformity, falls, pain, immobility, reduced bone health, nutritional/swallowing problems, communication barriers, and caregiver burden; these are reasonable consequences of severe complicated HSP but were not all specifically documented in the KLC4 family.

12. Treatment

Disease-modifying treatment

No approved or experimental KLC4-specific gene therapy, genome editing, RNA therapy, cell therapy, targeted drug, or immunotherapy was identified. Targeted ClinicalTrials.gov searches found no relevant KLC4 trial. The CRMP2-modulating compound lanthionine ketimine ester partly improved selected phenotypes in CLN6-deficient mouse neurons, but this does not establish efficacy or safety for KLC4 deficiency. (koh2021acln6crmp2klc4complex pages 11-14, koh2021acln6crmp2klc4complex pages 7-11)

Supportive care

Management should be individualized through neurology, rehabilitation medicine, medical genetics, ophthalmology, audiology, orthopedics, nutrition, and palliative/supportive services:

  • physiotherapy, stretching, positioning, gait aids, orthoses, wheelchairs, and contracture prevention;
  • occupational therapy and adaptive equipment;
  • speech-language therapy, augmentative communication, and swallowing assessment;
  • hearing aids or cochlear-implant evaluation where appropriate;
  • low-vision services and educational adaptations;
  • symptomatic treatment of spasticity, pain, seizures, sleep, bladder, or mood problems if present;
  • nutritional, respiratory, orthopedic, and bone-health surveillance.

These interventions are extrapolated from general neurorehabilitation/HSP practice; no KLC4-specific response rates or adverse-event data exist. Suggested NCIt intervention concepts include Physical Therapy, Occupational Therapy, Speech Therapy, Assistive Device, Hearing Aid, Cochlear Implantation, Genetic Counseling, and Supportive Care. Exact NCIt codes should be verified against the current release.

13. Prevention

Primary lifestyle or vaccine prevention is not applicable to a germline Mendelian disorder. Evidence-based prevention consists chiefly of reproductive genetics:

  • cascade testing for the known familial variant;
  • carrier testing of at-risk adult relatives;
  • preconception counseling;
  • prenatal diagnosis by chorionic-villus sampling or amniocentesis;
  • preimplantation genetic testing for monogenic disease, where legally and clinically available;
  • donor gametes or other reproductive options according to family preference.

Secondary prevention means prompt molecular diagnosis and early ophthalmologic, audiologic, neurologic, and rehabilitation intervention—not prevention of the molecular disease itself. Tertiary prevention targets contractures, falls, immobility, malnutrition, communication loss, and other complications. Population or newborn screening is unsupported because prevalence, assay performance, natural history, and effective presymptomatic treatment are unknown.

14. Other species and natural disease

No naturally occurring veterinary disease definitively attributable to orthologous KLC4 variants was identified, and there is no zoonotic transmission. Orthologous kinesin light-chain biology is conserved across vertebrates, but conservation of molecular function should not be equated with a recognized natural animal syndrome.

Relevant research taxa include human (Homo sapiens; NCBI Taxon 9606), zebrafish (Danio rerio; Taxon 7955), mouse (Mus musculus; Taxon 10090), and nematode (Caenorhabditis elegans; Taxon 6239). No breed ontology annotation is applicable.

15. Model organisms and experimental systems

Zebrafish

The strongest KLC4-specific functional model is the klc4^uw314 mutant zebrafish. Live imaging showed impaired stabilization of nascent Rohon–Beard sensory-axon branches, altered Rab5-positive endosomal movement and microtubule dynamics, reduced acetylated tubulin, abnormal peripheral-axon fasciculation, and loss of normal arbor tiling. Mutant larvae swam for a median 1.49 seconds versus 0.65 seconds after touch and completed 2 versus 1 median swim bouts; adults were viable and fertile but smaller and displayed anxiety-like behavior. (haynes2022klc4shapesaxon pages 12-14, haynes2022klc4shapesaxon pages 17-18, haynes2022klc4shapesaxon pages 10-12)

Strengths: intact vertebrate nervous system, developmental live imaging, measurable axonal transport and behavior. Limitations: the model did not reproduce early degeneration, deafness, blindness, intellectual disability, or the exact human deletion; behavioral phenotypes are not human clinical features. (haynes2022klc4shapesaxon pages 2-3)

The paper’s abstract states: “Using live imaging approaches in klc4 mutant zebrafish, we show that KLC4 is required for stabilization of nascent axon branches, proper microtubule (MT) dynamics, and endosomal transport.” It further reports that mutant larvae were hypersensitive to touch and adults showed anxiety-like behavior. Haynes et al., eLife, published 12 October 2022, DOI: https://doi.org/10.7554/eLife.74270. (haynes2022klc4shapesaxon pages 1-2, haynes2022klc4shapesaxon pages 17-18)

Mouse cortical neurons and PC12 cells

Biochemical and cellular studies identified a CLN6–CRMP2–KLC4 complex on neuronal vesicles and linked it to anterograde ER-derived-vesicle trafficking, neurite polarization, extension, and arborization. These systems are useful for cargo-interaction and transport studies, but because experiments principally altered CLN6, they are not direct models of KLC4-related disease. (koh2021acln6crmp2klc4complex pages 5-7, koh2021acln6crmp2klc4complex pages 1-5)

Needed next-generation models

Priority resources are patient-derived iPSCs differentiated into corticospinal, sensory, retinal, and auditory neurons; CRISPR-corrected isogenic controls; knock-in models carrying the exact human deletion; quantitative proteomics/cargo interactomics; long-term axonal degeneration assays; and rescue with wild-type KLC4. Such studies would test whether the disease results from transcript decay, truncated protein, defective cargo binding, or a combination.

Key abstract quotation from the human report

The defining abstract reports that the investigators studied “three affected individuals of a consanguineous family with progressive complicated spastic paraplegia,” identified a shared chromosome-6 homozygous region and “a homozygous 19-bp deletion in KLC4,” and concluded that the deletion produced a premature stop/truncated transcript and protein. This is the central direct human evidence; the broader pathophysiologic chain remains partly model-based. (bayrakli2015hereditaryspasticparaplegia pages 1-2)

Overall expert assessment

The most defensible current interpretation is a provisional ultra-rare autosomal-recessive kinesinopathy/complicated HSP caused by severe biallelic KLC4 loss of function. The segregation pattern, rarity, predicted domain loss, and conserved neuronal phenotypes are mutually consistent. Nevertheless, only one family has established the human phenotype, the precise disease-relevant cargo remains unknown, and no patient-neuron rescue experiment has yet completed the causal chain. Consequently, database entries should preserve the original observations, label model-based mechanisms explicitly as inferred, avoid assigning unverified ontology identifiers or population frequencies, and periodically reassess the association as new ClinVar submissions and independent cases emerge. (bayrakli2015hereditaryspasticparaplegia pages 4-6, haynes2022klc4shapesaxon pages 2-3, burnett2024therolesofa pages 19-24)

References

  1. (bayrakli2015hereditaryspasticparaplegia pages 1-2): Fatih Bayrakli, Hatice Gamze Poyrazoglu, Sirin Yuksel, Cengiz Yakicier, Bekir Erguner, Mahmut Samil Sagiroglu, Betul Yuceturk, Bugra Ozer, Selim Doganay, Bahattin Tanrikulu, Askin Seker, Fatih Akbulut, Ali Ozen, Huseyin Per, Sefer Kumandas, Yasemin Altuner Torun, Yasar Bayri, Mustafa Sakar, Adnan Dagcinar, and Ibrahim Ziyal. Hereditary spastic paraplegia with recessive trait caused by mutation in klc4 gene. Journal of Human Genetics, 60:763-768, Oct 2015. URL: https://doi.org/10.1038/jhg.2015.109, doi:10.1038/jhg.2015.109. This article has 34 citations and is from a peer-reviewed journal.

  2. (haynes2022klc4shapesaxon pages 2-3): Elizabeth M Haynes, Korri H Burnett, Jiaye He, Marcel W Jean-Pierre, Martin Jarzyna, Kevin W Eliceiri, Jan Huisken, and Mary C Halloran. Klc4 shapes axon arbors during development and mediates adult behavior. Oct 2022. URL: https://doi.org/10.7554/elife.74270, doi:10.7554/elife.74270. This article has 14 citations and is from a domain leading peer-reviewed journal.

  3. (burnett2024therolesofa pages 107-118): K Burnett. The roles of klc4 and clstn proteins in neuron morphogenesis and circuit function. Unknown journal, 2024.

  4. (bayrakli2015hereditaryspasticparaplegia pages 2-3): Fatih Bayrakli, Hatice Gamze Poyrazoglu, Sirin Yuksel, Cengiz Yakicier, Bekir Erguner, Mahmut Samil Sagiroglu, Betul Yuceturk, Bugra Ozer, Selim Doganay, Bahattin Tanrikulu, Askin Seker, Fatih Akbulut, Ali Ozen, Huseyin Per, Sefer Kumandas, Yasemin Altuner Torun, Yasar Bayri, Mustafa Sakar, Adnan Dagcinar, and Ibrahim Ziyal. Hereditary spastic paraplegia with recessive trait caused by mutation in klc4 gene. Journal of Human Genetics, 60:763-768, Oct 2015. URL: https://doi.org/10.1038/jhg.2015.109, doi:10.1038/jhg.2015.109. This article has 34 citations and is from a peer-reviewed journal.

  5. (bayrakli2015hereditaryspasticparaplegia pages 3-4): Fatih Bayrakli, Hatice Gamze Poyrazoglu, Sirin Yuksel, Cengiz Yakicier, Bekir Erguner, Mahmut Samil Sagiroglu, Betul Yuceturk, Bugra Ozer, Selim Doganay, Bahattin Tanrikulu, Askin Seker, Fatih Akbulut, Ali Ozen, Huseyin Per, Sefer Kumandas, Yasemin Altuner Torun, Yasar Bayri, Mustafa Sakar, Adnan Dagcinar, and Ibrahim Ziyal. Hereditary spastic paraplegia with recessive trait caused by mutation in klc4 gene. Journal of Human Genetics, 60:763-768, Oct 2015. URL: https://doi.org/10.1038/jhg.2015.109, doi:10.1038/jhg.2015.109. This article has 34 citations and is from a peer-reviewed journal.

  6. (bayrakli2015hereditaryspasticparaplegia pages 4-6): Fatih Bayrakli, Hatice Gamze Poyrazoglu, Sirin Yuksel, Cengiz Yakicier, Bekir Erguner, Mahmut Samil Sagiroglu, Betul Yuceturk, Bugra Ozer, Selim Doganay, Bahattin Tanrikulu, Askin Seker, Fatih Akbulut, Ali Ozen, Huseyin Per, Sefer Kumandas, Yasemin Altuner Torun, Yasar Bayri, Mustafa Sakar, Adnan Dagcinar, and Ibrahim Ziyal. Hereditary spastic paraplegia with recessive trait caused by mutation in klc4 gene. Journal of Human Genetics, 60:763-768, Oct 2015. URL: https://doi.org/10.1038/jhg.2015.109, doi:10.1038/jhg.2015.109. This article has 34 citations and is from a peer-reviewed journal.

  7. (haynes2022klc4shapesaxon pages 12-14): Elizabeth M Haynes, Korri H Burnett, Jiaye He, Marcel W Jean-Pierre, Martin Jarzyna, Kevin W Eliceiri, Jan Huisken, and Mary C Halloran. Klc4 shapes axon arbors during development and mediates adult behavior. Oct 2022. URL: https://doi.org/10.7554/elife.74270, doi:10.7554/elife.74270. This article has 14 citations and is from a domain leading peer-reviewed journal.

  8. (haynes2022klc4shapesaxon pages 17-18): Elizabeth M Haynes, Korri H Burnett, Jiaye He, Marcel W Jean-Pierre, Martin Jarzyna, Kevin W Eliceiri, Jan Huisken, and Mary C Halloran. Klc4 shapes axon arbors during development and mediates adult behavior. Oct 2022. URL: https://doi.org/10.7554/elife.74270, doi:10.7554/elife.74270. This article has 14 citations and is from a domain leading peer-reviewed journal.

  9. (haynes2022klc4shapesaxon pages 10-12): Elizabeth M Haynes, Korri H Burnett, Jiaye He, Marcel W Jean-Pierre, Martin Jarzyna, Kevin W Eliceiri, Jan Huisken, and Mary C Halloran. Klc4 shapes axon arbors during development and mediates adult behavior. Oct 2022. URL: https://doi.org/10.7554/elife.74270, doi:10.7554/elife.74270. This article has 14 citations and is from a domain leading peer-reviewed journal.

  10. (koh2021acln6crmp2klc4complex pages 5-7): SY Koh, JT Cain, H. Magee, K. White, M. Rechtzigel, B. Meyerink, H. Leppert, DJ Timm, JP Morgan, TB Johnson, B. Grove, R. Khanna, K. Hensley, J. Brudvig, and JM Weimer. A cln6-crmp2-klc4 complex regulates anterograde er-derived vesicle trafficking in cortical neurites. bioRxiv, Sep 2021. URL: https://doi.org/10.1101/2021.09.16.460653, doi:10.1101/2021.09.16.460653. This article has 4 citations.

  11. (koh2021acln6crmp2klc4complex pages 1-5): SY Koh, JT Cain, H. Magee, K. White, M. Rechtzigel, B. Meyerink, H. Leppert, DJ Timm, JP Morgan, TB Johnson, B. Grove, R. Khanna, K. Hensley, J. Brudvig, and JM Weimer. A cln6-crmp2-klc4 complex regulates anterograde er-derived vesicle trafficking in cortical neurites. bioRxiv, Sep 2021. URL: https://doi.org/10.1101/2021.09.16.460653, doi:10.1101/2021.09.16.460653. This article has 4 citations.

  12. (haynes2022klc4shapesaxon pages 1-2): Elizabeth M Haynes, Korri H Burnett, Jiaye He, Marcel W Jean-Pierre, Martin Jarzyna, Kevin W Eliceiri, Jan Huisken, and Mary C Halloran. Klc4 shapes axon arbors during development and mediates adult behavior. Oct 2022. URL: https://doi.org/10.7554/elife.74270, doi:10.7554/elife.74270. This article has 14 citations and is from a domain leading peer-reviewed journal.

  13. (koh2021acln6crmp2klc4complex pages 11-14): SY Koh, JT Cain, H. Magee, K. White, M. Rechtzigel, B. Meyerink, H. Leppert, DJ Timm, JP Morgan, TB Johnson, B. Grove, R. Khanna, K. Hensley, J. Brudvig, and JM Weimer. A cln6-crmp2-klc4 complex regulates anterograde er-derived vesicle trafficking in cortical neurites. bioRxiv, Sep 2021. URL: https://doi.org/10.1101/2021.09.16.460653, doi:10.1101/2021.09.16.460653. This article has 4 citations.

  14. (koh2021acln6crmp2klc4complex pages 7-11): SY Koh, JT Cain, H. Magee, K. White, M. Rechtzigel, B. Meyerink, H. Leppert, DJ Timm, JP Morgan, TB Johnson, B. Grove, R. Khanna, K. Hensley, J. Brudvig, and JM Weimer. A cln6-crmp2-klc4 complex regulates anterograde er-derived vesicle trafficking in cortical neurites. bioRxiv, Sep 2021. URL: https://doi.org/10.1101/2021.09.16.460653, doi:10.1101/2021.09.16.460653. This article has 4 citations.

  15. (burnett2024therolesofa pages 19-24): K Burnett. The roles of klc4 and clstn proteins in neuron morphogenesis and circuit function. Unknown journal, 2024.

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 5
Resolved 5
Unresolved (possible confabulation) 0
Unverifiable 0
References weighed for topical relevance 5
On topic 2
Off topic 0

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome Count
Terms checked 30
Resolved 30
Unresolved (possible confabulation) 0
Obsolete 0
Unverifiable 0

Every term resolved, and every label the report gave matched.